Materiały źródłowe

• #1 Myelofibrosis: Symptoms, Types, Prognosis & Treatment

  https://my.clevelandclinic.org/health/diseases/15672-myelofibrosis

  Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. Treatment goals mainly involve managing symptoms and conditions that arise, including anemia and an enlarged spleen. […] You dont need treatment unless youre experiencing symptoms. Still, your healthcare provider will monitor your condition even if you dont require immediate treatment. […] For most people, treatment goals are to manage conditions associated with myelofibrosis, including anemia and splenomegaly. […] Treatments can help manage symptoms that may be interfering with your day-to-day life. In the meantime, ask your provider to connect you with resources that can help you navigate the changes you may be experiencing. Palliative care and support groups are useful options when adjusting to a cancer diagnosis.

• #1 Identifying your Myelofibrosis Care Team

  https://www.mappingmf.com/charting-myelofibrosis/identifying-your-care-team/

  If you or someone you know has myelofibrosis (MF), getting the right care is key. MF symptoms can present and advance differently for everyone. Talk to your healthcare provider about any signs and symptoms you may be experiencing. Your healthcare provider can help refer you for the right testing and help you navigate potential treatment options. […] While your primary care physician or hematologist will often be taking the lead, it is common for your care team to include different specialists who are brought in based on your unique medical needs and symptom presentation. According to a poll of healthcare providers, 100% believe that collaboration across the extended oncology care team is essential. […] The caregiver is actually an important part of the care team. So it’s not simply the medical part of it. And of course, the patient is at the center of it. The caregiver actually is extremely important because it’s often the caregiver that when they come to the appointment that hears a lot of the information that might be missed by the patient, that can then provide a recap of what was said when they get home.

• #1 Myelofibrosis: Treatment Planning and Management

  https://www.onclive.com/view/myelofibrosis-treatment-planning-and-management

  For every patient I see with myelofibrosis, I make sure I do a risk stratification at the time of diagnosis and then subsequently follow-up using DIPSS [Dynamic International Prognostic Scoring System] or DIPSS Plus risk stratification schemas, so I can track their progress and see how they are doing. That is a crucial component: risk stratifying them. The second is symptom assessment. Frequently, our patients give a picture of being asymptomatic, or we dont assess symptoms thoroughly enough to elucidate every symptom they may have. If one uses a symptom assessment form, for example the MPN-SAF TSS [Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score], one may find more patient symptoms than what would appear initially. Its also important to get a rough estimation of all their symptoms and the severity. Those are 2 crucial things: No. 1, risk stratifying, and No. 2, identifying their symptoms and burden.

• #1 Key Patient Goals for Myelofibrosis Management

  https://www.oncnursingnews.com/view/key-patient-goals-for-myelofibrosis-management

  Key patient goals for managing myelofibrosis include improving quality of life by addressing low blood counts and constitutional symptoms, considering disease-modifying therapies and transplant to maximize longevity based on predicted survival, and incorporating personalized priorities through shared decision-making with their doctor when choosing treatments. […] Oncology nurses can help guide patients to the right supportive care for them.

• #1 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Patients who are symptom-free and have no signs of anemia, an enlarged spleen, or other complications at the time of diagnosis are generally not treated. Some people remain stable and symptom-free for many years. However, these patients still need to be monitored closely with regular medical checkups and tests to detect any signs and symptoms of disease progression. Treatment as part of a clinical trial is recommended if symptoms appear. […] The treatment approach for low-risk category patients who have symptoms of MF may be observation only. In certain circumstances, the doctor may prescribe cytoreductive treatment (a medication to lower blood cell counts) to help relieve the patients symptoms. […] Treatment options include: Participation in a clinical trial, Ruxolitinib (Jakafi), Peginterferon alfa-2a (Pegasys), Hydroxyurea (Hydrea) to relieve symptoms caused by high blood counts, Pacritinib (Vonjo) if the platelet count is less than 50,000, Momelotinib (Ojjaara), Fedratinib (Inrebic).

• #1 Considerations to comprehensive care for the older individual with myelofibrosis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/36333065/

  Over the last decade, we have witnessed a massive increase in available clinical agents, both in the clinical trial setting and following commercial use approval, directed to reduced life expectancy as well as the considerable symptom, splenic and anaemia burden associated with myelofibrosis. […] Given the median age of onset of the disease, coupled with an ageing population globally, we will be caring for an increasingly aged myelofibrosis cohort in future years. […] We will need to adapt our approach, emphasizing the holistic management of the older individual with myelofibrosis accordingly. […] Out with the pharmacological management of the disease, consideration needs to be given to interventions based on concurrent illness, comprehensive geriatric assessments, frailty, polypharmacy and drug-drug interactions, nutritional issues, psychological concerns (depression, anxiety or distress), cognitive decline and social/economic aspects. […] Within this review, we summarise available data addressing these issues, outline knowledge gaps and suggest a summative and holistic approach to the older individual with myelofibrosis.

• #1 Patient Advocacy in Myelofibrosis Care

  https://www.pharmacytimes.com/view/patient-advocacy-in-myelofibrosis-care

  Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management. […] In this segment, Mahmoudjafari directs a discussion with Nachar on the crucial role patients play in advocating for themselves and improving access to myelofibrosis treatments. Nachar emphasizes the significance of patient education on navigating the health care system and accessing medications. […] The conversation highlights the pivotal role of pharmacists in advocating for patients during multidisciplinary discussions, considering socioeconomic factors, and ensuring appropriate therapy selection. […] The discussion underscores the collaborative and proactive approach pharmacists employ to enhance patient outcomes and quality of life.

• #1 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Treatment options for higher risk patients include: Allogeneic stem cell transplant, Participation in a clinical trial, Pacritinib (Vonjo) (preferred regimen) or momelotinib (Ojjaara). […] For patients with anemia, the treatment approach depends on whether MF symptoms are present and, if present, on how well drug therapy is controlling these symptoms. […] Treatment may include: Participation in a clinical trial, Luspatercept-aamt (Reblozyl), Erythropoiesis (EPO)-stimulating agents (ESA) if EPO level is lower than 500 mU/mL, Momelotinib (Ojjaara), Pacritinib (Vonjo), Receive red blood cell transfusions. […] Allogeneic stem cell transplantation is the only current treatment with the potential to cure MF, but it also carries a high risk of life-threatening side effects. It is usually risky for older patients and those individuals with other health problems. Therefore, it is recommended for younger patients with no other pre-existing health problems. However, allogeneic stem cell transplantation can be used in older people when medically appropriate.

• #1 Myelofibrosis: Self-Care Tips

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-self-care

  Myelofibrosis (a form of blood cancer) can be a long-term condition, but taking good care of yourself can help you enjoy a happier, healthier life. […] If myelofibrosis has pulled you away from work, your spirits may get a boost if you go back when you’re up to it. That can help you feel like you’re back to your normal life and get you out of the house and around other people. […] If you think fatigue or other effects of myelofibrosis could affect your work: Ask your boss if you can start part-time or work on a flexible schedule. Be patient with yourself as you build up your strength and mental focus. You might ask your doctor to write a letter explaining what myelofibrosis is and how it can affect you. […] Your medical team can help you get your weight in line.

• #1 Myelofibrosis | Nebraska Hematology Oncology – Cancer Care Treatment Blood Disorders Clinical Trials Lincoln Nebraska (NE)

  https://www.yourcancercare.com/types-of-cancer/myeloproliferative-neoplasms-mpn/myelofibrosis

  Other drugs may also be used to manage symptoms and to reduce the occurrence or severity of complications from myelofibrosis. […] Blood transfusions: Periodic blood transfusions may be necessary to manage anemia. […] Splenectomy or radiation to the spleen: Surgical removal of the spleen (splenectomy) or radiation to the spleen may be necessary if drug treatment doesnt adequately manage spleen size and blood counts. […] Stem cell transplantation: For carefully selected patients with high- or intermediate-risk myelofibrosis, an allogeneic stem cell transplant (ASCT) may be an option. ASCT is the only potentially curative treatment for myelofibrosis, but can produce life-threatening side effects. The procedure involves high doses of chemotherapy or radiation to destroy the unhealthy bone marrow. Blood-forming stem cells from a healthy, matched donor are then infused into the patient. A reduced-intensity allogeneic stem cell transplant may also be an option for some patients. This procedure uses lower doses of chemotherapy or radiation.

• #1 Standard care and investigational drugs in the treatment of myelofibrosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6788389/

  Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly, constitutional symptoms, ineffective hematopoiesis, and an increased risk of leukemic transformation. […] Current therapeutic interventions are only partially effective with only allogeneic stem cell transplant potentially curative. […] Drug discontinuation is associated with a dismal outcome. […] Currently, there are no US Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved drugs for the treatment of anemia, with or without red blood cell (RBC) transfusion dependence, and thrombocytopenia in MF, but commonly used drugs include corticosteroids, androgenic steroids, erythropoietin, and immunomodulatory drugs (such as thalidomide, lenalidomide, and pomalidomide). […] Furthermore, given the detrimental effects of anemia and transfusion-related iron overload, a proper iron chelation therapy is crucial and seems to be effective on outcome of disease, in particular in terms of hematologic improvement and survival.

• #1 Myelofibrosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelofibrosis/diagnosis-treatment/drc-20355062

  Our caring team of Mayo Clinic experts can help you with your myelofibrosis-related health concerns […] Palliative care is a special type of healthcare that helps people with serious illnesses feel better. If you have cancer, palliative care can help relieve pain and other symptoms. A team of healthcare professionals gives palliative care. This can include doctors, nurses and other specially trained health professionals. Their goal is to improve quality of life for you and your family. […] When palliative care is used along with all of the other treatments, people with cancer may feel better and live longer.

• #1 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis […] The symptoms and side effects of myelofibrosis are unique to each person, making a personalized approach to managing them essential. As a result, you will work closely with a multidisciplinary health care team that will help you manage the disease so you can maintain a good quality of life. […] Your team will draw on a broad range of services known as palliative care or supportive care. Palliative care is often confused with hospice care, but palliative care services may be used at any time during the cancer care continuum, while hospice focuses on end-of-life care. […] Supportive care addresses the physical, emotional, practical, spiritual, financial and family-related challenges of people diagnosed with cancer and their loved ones. […] Supportive care often focuses on managing physical symptoms such as fatigue, weight loss, bone and joint pain, fever, rash, night sweats, gout, headaches, Graft-versus-Host Disease (GvHD), diarrhea, mouth sores, nausea and vomiting, and abdominal pain due to an enlarged liver or spleen.

• #1 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis interferes with the development of healthy blood cells and frequently causes anemia. When someone is anemic, they do not have enough red blood cells to carry oxygen throughout the body. This results in symptoms of fatigue, shortness of breath, feeling cold and looking pale. […] Regardless of the cause of anemia, your supportive care team will help you manage it. Therapies used include androgens, blood transfusions, corticosteroids, erythropoiesis stimulating agents and immunomodulators. In some cases, your doctor may recommend supplements to replace low levels of iron, folate or vitamin B12. […] Other therapies for anemia are being researched in clinical trials. Ask your doctor whether you may be a candidate for one. […] In the meantime, there are some actions you can take to ease the fatigue caused by the anemia. Tell your doctor if you are feeling weak and tired; get enough sleep; take a walk; eat a well-balanced diet; and perform activities that bring you joy.

• #1 Myelofibrosis, Cancer, Information, Resources

  https://www.cancercare.org/diagnosis/myelofibrosis

  Cancer Care provides free, professional support services for people affected by myelofibrosis, as well as myelofibrosis treatment information and financial help with cancer-related costs and treatment co-pays. […] Oncology social workers help you cope with the emotional and practical challenges of myelofibrosis. […] People coping with serious conditions may feel many strong emotions and its common to need extra support to help get through difficult times. Patients and family members can benefit from counseling. Cancer Care services include telephone and online support groups for people with cancer and their loved ones. […] Myelofibrosis is the rarest of the MPNs and this can make finding information and support more of a challenge. Fortunately, you dont have to travel that road alone, and there are a number of groups that can assist.

• #1 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  There is not one treatment that is effective for all myelofibrosis (MF) patients. Patients have varying symptoms and circumstances that require different treatment options. Some MF patients remain symptom-free for many years and do not require immediate treatment. All MF patients, however, need to be closely monitored. […] There is no drug therapy that can cure MF. The only potential cure for MF is allogeneic stem cell transplantation. But this procedure is risky for older patients and those with other health problems. Because MF primarily affects older adults, a stem cell transplantation is not a treatment option for most MF patients. For most people with MF, treatment remains aimed at controlling disease symptoms and complications, enhancing quality of life and extending survival. […] For patients without anemia, the treatment approach is based on the patients prognostic level as well as the presence and severity of MF symptoms.

• #1 Patient-Centered Care in Myelofibrosis: Managing Expectations and Quality-of-Life Outcomes

  https://www.targetedonc.com/view/patient-centered-care-in-myelofibrosis-managing-expectations-and-quality-of-life-outcomes

  Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and careful attention to patient goals and expectations. […] The American Society of Clinical Oncology and the Community Oncology Alliance released new Oncology Medical Home standards that are designed to help guide care providers as they treat patients.

• #1 Get Myelofibrosis Care | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelofibrosis-treatment

  If your symptoms are getting in the way of your quality of life, your provider may recommend palliative care. You get a support network of providers experienced in helping you navigate your diagnosis and treatment physically, mentally, emotionally and spiritually. […] Once treatment is done, youll move to the next phase follow-up care. This means youll have regular visits with your care team and do tests to make sure the cancer hasnt come back. Staying in touch with your providers like this means that we can catch a recurrence early and quickly start treatment.

• #1 Myelofibrosis: Follow-Up Care After Treatment

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-aftercare

  If youve been diagnosed with myelofibrosis, a kind of cancer that affects your blood, follow-up care can be almost as important as your initial treatment. […] Your medical team will want to keep a close eye on the number of red and white blood cells and platelets you have. You’ll also want to be on the lookout for any familiar symptoms of myelofibrosis, like anemia (when your body isn’t making enough red blood cells). […] Communication with your doctors during these visits is key. […] Sometimes life can be hard after treatment for cancer. You might feel depressed, anxious, or lonely. Survivorship is a newer form of follow-up care that can help support your emotional and mental health. […] A good survivorship plan should include: a treatment summary, a description of the follow-up appointments and tests you’ll need and how often, tips on self-care, an understanding of possible side effects of treatment and how to manage them, and ways you can address your physical and mental health.

• #1 Myelofibrosis (MF) – Leukaemia Care

  https://www.leukaemiacare.org.uk/support-and-information/information-about-blood-cancer/blood-cancer-information/about-myeloproliferative-neoplasms-mpn/myelofibrosis-mf/

  Myelofibrosis (MF) is a slow-growing blood cancer that causes scarring in your bone marrow. This stops it from making enough healthy blood cells. Treatment for MF aims to manage symptoms and other health problems that can develop over time, such as anaemia and a swollen spleen. […] Most people who need treatment for MF take tablets called JAK inhibitors. Other options include oral chemotherapy or peginterferon injections. […] You may also need treatments to prevent or manage complications of MF. […] Your haematology team will regularly check you for signs and symptoms of transformation. If it happens, you will need treatment for AML. […] Your doctor will regularly monitor your MF and offer you treatment if you need it. Not everyone needs treatment straight away. If you are in a lower MF risk group, you may be on active monitoring instead.

• #1 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  Although these agents are effective in reducing spleen size and improving symptoms, they do not affect disease progression. Therefore, I also evaluate all patients for allogeneic stem cell transplantation, which is the only curative modality. Appropriate patients are younger than age 75, with a low comorbidity burden and either intermediate-2 or high-risk disease. In addition, patients who do not respond to frontline JAK inhibitors should be considered for this approach. In patients who are transplant candidates, I will concurrently have them evaluated and start the process of finding a donor while initiating a JAK inhibitor. […] What are the most common adverse effects of JAK inhibitors, and how do you help patients manage these issues? There are short- and long-term effects of JAK inhibitors. Focusing on ruxolitinib, the most frequently used JAK inhibitor, patients can experience bruising, dizziness, and headaches, which generally resolves within a few weeks. Notable longer-term adverse events of ruxolitinib include increased rates of shingles infection, so I encourage my patients to get vaccinated for shingles before initiation. Weight gain has also been reported with ruxolitinib, but not with other JAK inhibitors. The other main adverse effect of ruxolitinib is worsening anemia and thrombocythemia, so I closely monitor blood counts during treatment.

• #1 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  Patients with myelofibrosis have unique presentations and each patient has unique therapeutic needs that requires collaboration between the physician, the nurse, the nurse practitioner, that pharmacist the whole health care system to try to provide better care, Yacoub said. […] There is also a significant education need for practitioners, as well as the patients and their caregivers to teach them more about myelofibrosis, how to approach the disease, and [identify] the unmet needs so that we can work as a team to advance the field. […] The best avenue for the management of patients with myelofibrosis can evolve over time, Yacoub said, but noted that 3 goals are commonreduce splenomegaly, improve symptoms, and improve survival. […] This is a unique feature of MPNs which requires extra attention and examination by providers, Yacoub said.

• #1 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Taking part in a clinical trial may be the best treatment choice for some myelofibrosis (MF) patients. Patient participation in clinical trials is important in the development of new and more effective treatments for MF and may provide patients with additional treatment options. […] Certain factors can affect a patients prognosis (a persons chance of recovery or the likely outcome of their disease). These are called prognostic factors, and they help doctors predict how a patients disease is likely to respond to treatment. These factors help doctors plan the most appropriate treatment for each patient. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers. It is important for patients and the members of their medical team to discuss all treatment options, including treatments being studied in clinical trials.

• #1 Primary myelofibrosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myeloproliferative-neoplasms/primary-myelofibrosis/

  Primary myelofibrosis (also called chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. Over time, this leads to progressive bone marrow failure. […] For others treatment is largely supportive and is aimed at preventing complications due to low blood counts and an enlarged spleen (splenomegaly). This involves making every effort to improve your quality of life, by relieving any symptoms of anaemia or an enlarged spleen, and preventing and treating any complications that might arise from your disease or its treatment. This may include periodic blood transfusions, biotherapy or chemotherapy. Antibiotics may be needed to prevent and treat any infections. […] Your doctor is the best person to give you an accurate prognosis regarding your disease as he or she has all the necessary information to make this assessment.

• #1 ASH 2024 Symposia on MF Care – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/ash-24-peerview-mf-session-coverage

  While managing myelofibrosis requires a great deal of care and consideration, the ongoing dedication to research and innovation provides hope for better outcomes. […] New data, evolving guidelines, and innovative therapies pave the way for a brighter future. Patients and caregivers are encouraged to stay informed, advocate for personalized care, and consider clinical trials when possible. […] By understanding the nuances of myelofibrosis treatment shared during this session, patients and caregivers can better engage with their healthcare teams and make informed decisions about their care.

• #2

  https://www.accc-cancer.org/home/learn/cancer-types/hematologic-malignancies/advancements-in-treating-patients-with-myelofibrosis-and-strategies-to-improve-care

  Myelofibrosis is a rare type of cancer that affects the bone marrow by disrupting the body’s production of blood cells and is a type of myeloproliferative neoplasm (MPN). […] Symptoms and effects of myelofibrosis include scarring within a patients bone marrow, severe anemia that leads to fatigue and weakness, and an enlarged spleen. […] Therefore, treatment for myelofibrosis often focuses on relieving symptoms rather than a cure. […] ACCC has published a new resource to help health care providers determine the treatment trajectory in patients with myelofibrosis. […] The goal of treatment for most patients with myelofibrosis is to relieve symptoms. […] ACCCBuzz spoke with Dr. Gabriela Hobbs, MD, at Massachusetts General Hospital Cancer Center to learn how to best manage patients’ care for those with myelofibrosis. […] ACCCBuzz spoke with Julie Huynh-Lu, PA-Cphysician assistant in the Department of Leukemia at the University of Texas MD Anderson Cancer Centerto learn more about enhancing the care for patients with myelofibrosis by assessing and addressing their psychosocial and financial health.

• #2 Myelofibrosis – Care at Mayo Clinic – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelofibrosis/care-at-mayo-clinic/mac-20355065

  Mayo Clinic doctors draw on their experience caring for people with myelofibrosis to provide you with a personalized treatment plan. The experts at Mayo Clinic Comprehensive Cancer Center work together to provide you with the exact care you need. […] At Mayo Clinic, hematologists and transplant specialists work as a multidisciplinary team to care for people with myelofibrosis. Other doctors and healthcare professionals are included as needed. […] People with myelofibrosis who seek care at Mayo Clinic have access to clinical trials based on the latest treatment advances. […] Mayo Clinic doctors will work with you to review all of your treatment options and choose the treatment that best suits your needs and goals. The range of treatments offered to people with myelofibrosis includes medicines, blood transfusions, chemotherapy, targeted therapy, surgery to remove the spleen (splenectomy) and bone marrow transplant.

• #2 Myelofibrosis: Treatment Planning and Management

  https://www.onclive.com/view/myelofibrosis-treatment-planning-and-management

  What is the best approach for monitoring response to therapy? For every patient I see, I obtain a CBC [complete blood count], a symptom assessment at every visit, and possibly a radiological assessment of their spleen size every few months. This is crucial. We want to keep track of how the patient is doing in terms of their symptoms and also take a look at their blood counts to see if they are having any signs of progression, stability, or adverse events from their treatments. In the event one were to see, for example, a drop in platelet count or hemoglobin level, or a rise in white blood cell count, or an increase or new emergence of peripheral blood blasts, or for example, in the event of having worsening splenomegaly or new symptoms that emerge on stable doses of JAK inhibitors, one may be worried about a potential resistance or relapse/refractoriness to therapy. That is when the consideration for switching therapy to something else comes about. That something else could be in the form of hypomethylating agents or intensive chemotherapy, should the patient have had a definite progression of their underlying myelofibrosis, or to an alternative JAK inhibitor.

• #2 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis interferes with the development of healthy blood cells and frequently causes anemia. When someone is anemic, they do not have enough red blood cells to carry oxygen throughout the body. This results in symptoms of fatigue, shortness of breath, feeling cold and looking pale. […] Regardless of the cause of anemia, your supportive care team will help you manage it. Therapies used include androgens, blood transfusions, corticosteroids, erythropoiesis stimulating agents and immunomodulators. In some cases, your doctor may recommend supplements to replace low levels of iron, folate or vitamin B12. […] Other therapies for anemia are being researched in clinical trials. Ask your doctor whether you may be a candidate for one. […] In the meantime, there are some actions you can take to ease the fatigue caused by the anemia. Tell your doctor if you are feeling weak and tired; get enough sleep; take a walk; eat a well-balanced diet; and perform activities that bring you joy.

• #2 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  Although these agents are effective in reducing spleen size and improving symptoms, they do not affect disease progression. Therefore, I also evaluate all patients for allogeneic stem cell transplantation, which is the only curative modality. Appropriate patients are younger than age 75, with a low comorbidity burden and either intermediate-2 or high-risk disease. In addition, patients who do not respond to frontline JAK inhibitors should be considered for this approach. In patients who are transplant candidates, I will concurrently have them evaluated and start the process of finding a donor while initiating a JAK inhibitor. […] What are the most common adverse effects of JAK inhibitors, and how do you help patients manage these issues? There are short- and long-term effects of JAK inhibitors. Focusing on ruxolitinib, the most frequently used JAK inhibitor, patients can experience bruising, dizziness, and headaches, which generally resolves within a few weeks. Notable longer-term adverse events of ruxolitinib include increased rates of shingles infection, so I encourage my patients to get vaccinated for shingles before initiation. Weight gain has also been reported with ruxolitinib, but not with other JAK inhibitors. The other main adverse effect of ruxolitinib is worsening anemia and thrombocythemia, so I closely monitor blood counts during treatment.

• #2 Myelofibrosis: Follow-Up Care After Treatment

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-aftercare

  If youve been diagnosed with myelofibrosis, a kind of cancer that affects your blood, follow-up care can be almost as important as your initial treatment. […] Your medical team will want to keep a close eye on the number of red and white blood cells and platelets you have. You’ll also want to be on the lookout for any familiar symptoms of myelofibrosis, like anemia (when your body isn’t making enough red blood cells). […] Communication with your doctors during these visits is key. […] Sometimes life can be hard after treatment for cancer. You might feel depressed, anxious, or lonely. Survivorship is a newer form of follow-up care that can help support your emotional and mental health. […] A good survivorship plan should include: a treatment summary, a description of the follow-up appointments and tests you’ll need and how often, tips on self-care, an understanding of possible side effects of treatment and how to manage them, and ways you can address your physical and mental health.

• #2

  https://hhoaltd.navigatingcare.com/library/myeloproliferative/learn/treatment-of-primary-myelofibrosis

  Treatment of primary myelofibrosis in patients without signs or symptoms is usually watchful waiting. […] Patients with primary myelofibrosis may have signs or symptoms of anemia. Anemia is usually treated with transfusion of red blood cells to relieve symptoms and improve quality of life. In addition, anemia may be treated with: Erythropoietic growth factors. Prednisone. Danazol. Thalidomide, lenalidomide, or pomalidomide, with or without prednisone. […] Treatment of primary myelofibrosis in patients with other signs or symptoms may include the following: Targeted therapy with ruxolitinib. Chemotherapy. Donor stem cell transplant. Thalidomide, lenalidomide, or pomalidomide. Splenectomy. Radiation therapy to the spleen, lymph nodes, or other areas outside the bone marrow where blood cells are forming. Immunotherapy (interferon alfa). Erythropoietic growth factors. A clinical trial of other targeted therapy drugs.

• #2 Myelofibrosis: Self-Care Tips

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-self-care

  Myelofibrosis (a form of blood cancer) can be a long-term condition, but taking good care of yourself can help you enjoy a happier, healthier life. […] If myelofibrosis has pulled you away from work, your spirits may get a boost if you go back when you’re up to it. That can help you feel like you’re back to your normal life and get you out of the house and around other people. […] If you think fatigue or other effects of myelofibrosis could affect your work: Ask your boss if you can start part-time or work on a flexible schedule. Be patient with yourself as you build up your strength and mental focus. You might ask your doctor to write a letter explaining what myelofibrosis is and how it can affect you. […] Your medical team can help you get your weight in line.

• #2 Myelofibrosis | Nebraska Hematology Oncology – Cancer Care Treatment Blood Disorders Clinical Trials Lincoln Nebraska (NE)

  https://www.yourcancercare.com/types-of-cancer/myeloproliferative-neoplasms-mpn/myelofibrosis

  Other drugs may also be used to manage symptoms and to reduce the occurrence or severity of complications from myelofibrosis. […] Blood transfusions: Periodic blood transfusions may be necessary to manage anemia. […] Splenectomy or radiation to the spleen: Surgical removal of the spleen (splenectomy) or radiation to the spleen may be necessary if drug treatment doesnt adequately manage spleen size and blood counts. […] Stem cell transplantation: For carefully selected patients with high- or intermediate-risk myelofibrosis, an allogeneic stem cell transplant (ASCT) may be an option. ASCT is the only potentially curative treatment for myelofibrosis, but can produce life-threatening side effects. The procedure involves high doses of chemotherapy or radiation to destroy the unhealthy bone marrow. Blood-forming stem cells from a healthy, matched donor are then infused into the patient. A reduced-intensity allogeneic stem cell transplant may also be an option for some patients. This procedure uses lower doses of chemotherapy or radiation.

• #2 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Patients who are symptom-free and have no signs of anemia, an enlarged spleen, or other complications at the time of diagnosis are generally not treated. Some people remain stable and symptom-free for many years. However, these patients still need to be monitored closely with regular medical checkups and tests to detect any signs and symptoms of disease progression. Treatment as part of a clinical trial is recommended if symptoms appear. […] The treatment approach for low-risk category patients who have symptoms of MF may be observation only. In certain circumstances, the doctor may prescribe cytoreductive treatment (a medication to lower blood cell counts) to help relieve the patients symptoms. […] Treatment options include: Participation in a clinical trial, Ruxolitinib (Jakafi), Peginterferon alfa-2a (Pegasys), Hydroxyurea (Hydrea) to relieve symptoms caused by high blood counts, Pacritinib (Vonjo) if the platelet count is less than 50,000, Momelotinib (Ojjaara), Fedratinib (Inrebic).

• #2 A myelofibrosis survivor’s stem cell transplant advice | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/a-myelofibrosis-survivors-stem-cell-transplant-advice.h00-159149190.html

  Myelofibrosis is typically treated with a stem cell transplant, so I started working with Uday Popat, M.D., to find a donor. […] Luckily, I had two perfect unrelated matches through Be the Match, the National Marrow Donor Program. We scheduled the transplant for Feb. 3, 2016. I recovered quickly with very few side effects so I ended up leaving the hospital two weeks early. […] Preparing for a stem cell transplant is tough, so my advice to anyone facing one is to go in as strong as you can. Work out until the day you enter the hospital, and dont pass up the cherry pie. […] Recovering from a stem cell transplant is like a marathon, not a sprint.

• #2 Myelofibrosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelofibrosis/diagnosis-treatment/drc-20355062

  Our caring team of Mayo Clinic experts can help you with your myelofibrosis-related health concerns […] Palliative care is a special type of healthcare that helps people with serious illnesses feel better. If you have cancer, palliative care can help relieve pain and other symptoms. A team of healthcare professionals gives palliative care. This can include doctors, nurses and other specially trained health professionals. Their goal is to improve quality of life for you and your family. […] When palliative care is used along with all of the other treatments, people with cancer may feel better and live longer.

• #2 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis […] The symptoms and side effects of myelofibrosis are unique to each person, making a personalized approach to managing them essential. As a result, you will work closely with a multidisciplinary health care team that will help you manage the disease so you can maintain a good quality of life. […] Your team will draw on a broad range of services known as palliative care or supportive care. Palliative care is often confused with hospice care, but palliative care services may be used at any time during the cancer care continuum, while hospice focuses on end-of-life care. […] Supportive care addresses the physical, emotional, practical, spiritual, financial and family-related challenges of people diagnosed with cancer and their loved ones. […] Supportive care often focuses on managing physical symptoms such as fatigue, weight loss, bone and joint pain, fever, rash, night sweats, gout, headaches, Graft-versus-Host Disease (GvHD), diarrhea, mouth sores, nausea and vomiting, and abdominal pain due to an enlarged liver or spleen.

• #2 Get Myelofibrosis Care | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelofibrosis-treatment

  If your symptoms are getting in the way of your quality of life, your provider may recommend palliative care. You get a support network of providers experienced in helping you navigate your diagnosis and treatment physically, mentally, emotionally and spiritually. […] Once treatment is done, youll move to the next phase follow-up care. This means youll have regular visits with your care team and do tests to make sure the cancer hasnt come back. Staying in touch with your providers like this means that we can catch a recurrence early and quickly start treatment.

• #2 Get Myelofibrosis Care | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelofibrosis-treatment

  Providers from different specialties come together as a care team that plans your treatment, keeps an eye on your progress and guides you through recovery and follow-up care. We build this team based on your unique needs and diagnosis. […] Our experts take the time to listen and answer your questions. We want to hear how myelofibrosis affects your life, so we can choose the best treatments ones that lessen your side effects, slow disease progression and help you keep doing the activities you love. […] This team stays with you throughout your diagnosis, treatment and beyond. They meet weekly to talk about your progress and adjust your treatment plan as needed. […] Your care team explores all options, including the latest clinical trials, as they craft the most personalized treatment plan. We dont just plan the medical side of things we also consider your goals and quality of life to be sure you get the latest treatment that focuses on you.

• #2 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Taking part in a clinical trial may be the best treatment choice for some myelofibrosis (MF) patients. Patient participation in clinical trials is important in the development of new and more effective treatments for MF and may provide patients with additional treatment options. […] Certain factors can affect a patients prognosis (a persons chance of recovery or the likely outcome of their disease). These are called prognostic factors, and they help doctors predict how a patients disease is likely to respond to treatment. These factors help doctors plan the most appropriate treatment for each patient. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers. It is important for patients and the members of their medical team to discuss all treatment options, including treatments being studied in clinical trials.

• #2 Considerations to comprehensive care for the older individual with myelofibrosis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/36333065/

  Over the last decade, we have witnessed a massive increase in available clinical agents, both in the clinical trial setting and following commercial use approval, directed to reduced life expectancy as well as the considerable symptom, splenic and anaemia burden associated with myelofibrosis. […] Given the median age of onset of the disease, coupled with an ageing population globally, we will be caring for an increasingly aged myelofibrosis cohort in future years. […] We will need to adapt our approach, emphasizing the holistic management of the older individual with myelofibrosis accordingly. […] Out with the pharmacological management of the disease, consideration needs to be given to interventions based on concurrent illness, comprehensive geriatric assessments, frailty, polypharmacy and drug-drug interactions, nutritional issues, psychological concerns (depression, anxiety or distress), cognitive decline and social/economic aspects. […] Within this review, we summarise available data addressing these issues, outline knowledge gaps and suggest a summative and holistic approach to the older individual with myelofibrosis.

• #2 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  How do you monitor for disease progression? I will discuss with patients how they are feeling in order to determine if there are any new or developing symptoms that could be a sign that their disease is progressing. I will also review their laboratory work looking for changes in blood counts that could be a signal of disease evolution. […] For instance, development of anemia or thrombocytopenia may signal worsening bone marrow function or progression to secondary acute leukemia. If there are concerning signs or symptoms, I will then perform a bone marrow biopsy with aspirate that will include assessment of mutations and chromosomal abnormalities to determine if their disease is progressing. […] What are the first-line treatment options for a patient newly diagnosed with myelofibrosis, and how do you determine the best course of action? For patients with myelofibrosis, the first-line treatment options include Janus kinase (JAK) inhibitors, which are effective at improving spleen size and reducing symptom burden. The US Food and Drug Administration (FDA) has approved 4 JAK inhibitors for the treatment of myelofibrosis: ruxolitinib, fedratinib, pacritinib, and momelotinib. In general, ruxolitinib is the first-line treatment option unless there is thrombocytopenia, in which case pacritinib is more appropriate. In patients with baseline anemia, momelotinib may be the best choice.

• #2 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  There have been tools developed to quantify patients symptoms and address them appropriately. […] Finally, Yacoub noted that patients are treated based on symptom burden and risk. […] Despite guidelines for these treatments, the time to progression in myelofibrosis varies with most experiencing progression in the first 10 years of a diagnosis. […] Long-term, progressive complications such as cytopenias, constitutional symptoms, organomegaly and extramedullary hematopoiesis have been reported, as well as short-term vascular events. […] There is also the potential for evolution to leukemia, which Yacoub noted makes the unmet need for patients who progress on JAK inhibitors of importance. […] Its important that, in addition to your clinical lab studies, symptoms are subjective and objective and its always important to communicate with your patients, Galinsky said.

• #2 Tailoring Myelofibrosis Care: Patient Preferences and Challenges

  https://www.pharmacytimes.com/view/tailoring-myelofibrosis-care-patient-preferences-and-challenges

  Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration. […] Griffin emphasizes the pharmacists role in symptom management, using tools like the Myeloproliferative Neoplasm Symptom Assessment Form, and highlights the importance of identifying and addressing specific symptoms that matter most to each patient. […] He underscores the flexibility provided by the array of available therapies, enabling tailored approaches beyond conventional options. […] Mancini acknowledges the progress made in integrating pharmacists into oncology care teams but notes challenges related to new roles and managing mail order complexities. […] He emphasizes the importance of persistently demonstrating value, even if not every recommendation is accepted, and highlights ongoing battles with insurance and mail order issues. […] The discussion reveals opportunities for pharmacists in tailoring therapies and navigating challenges in collaborative care for myelofibrosis patients.

• #2 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  What are some of the key reasons why patients may develop JAK inhibitor resistance or intolerance, and how do you address these problems in clinical practice? There are a variety of reasons why patients discontinue a JAK inhibitor, but these can be lumped into 2 categories: (1) the medication has not achieved, or is no longer achieving, treatment goals, or (2) adverse effects from the JAK inhibitor require discontinuation. In a large series of patients with myelofibrosis who were treated with ruxolitinib, about 60% of discontinuations were because of JAK inhibitor refractoriness/resistance, and around 40% were from adverse events. […] Resistance can arise from several mechanisms, including activation of alternative pathways and clonal evolution that are ongoing regardless of JAK inhibition. In clinical practice, we are addressing JAK inhibitor resistance through clinical trials of novel therapies, particularly in combination with JAK inhibitors, which can potentially mitigate resistance. New JAK inhibitors are also being developed that may more effectively target the overactive JAK-signal transducer and activator of transcription (STAT) pathway and reduce resistance.

• #2 Myelofibrosis (MF) | Cancer Support Community

  https://www.cancersupportcommunity.org/myelofibrosis-mf

  Find educational resources and tips to cope with myelofibrosis (MF). This rare blood disease develops when the bone marrow makes too many blood cells. […] Check out this article about caregiving for a loved one with myelofibrosis. […] Check out this article about coping with myelofibrosis. […] Check out this article about managing symptoms of myelofibrosis. […] Check out this webpage with information about myelofibrosis. […] Learn more about MF using this resource. […] Watch this short video about the treatment options for myelofibrosis.

• #2 What Is Myelofibrosis (MF)? | Primary Myelofibrosis

  https://www.voicesofmpn.com/myelofibrosis-information

  Don’t be afraid to talk to your doctor. You have to be proactive. You need to inform them what’s going on in your life. You need to tell them how you’re feeling. […] To try to help control the signs and symptoms of MF, Healthcare Professionals use therapies such as blood transfusions, radiation, removal of the spleen, and stem cell transplantation. People with MF may be prescribed other treatments, including but not limited to chemotherapy drugs. […] Regular monitoring and medical supervision can help identify signs of disease progression and help minimize the risk of complications. […] When you’re living with MF, you may find yourself saying that you’re fine even when you might not be. But when you don’t speak up and share how you really feel, you may miss out on the opportunity to get the care and support that you need and deserve. […] Remember, changes in your MF symptoms could be a sign that your MF is changing, too. So be sure to spell out how you really feel. Because fine is not enough.

• #2 Standard care and investigational drugs in the treatment of myelofibrosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6788389/

  The therapeutic landscape in MF has significantly improved, and emerging drugs with different target pathways, alone or in combination with ruxolitinib, seem promising. […] Ruxolitinib is the only approved therapy for MF by the US Food and Drug Administration. […] The unraveling, albeit partial, of cellular pathways underlying disease occurrence and progression has led the way to the development of targeted treatments; however, the only curative strategy is allogeneic stem cell transplant (ASCT). […] This review is focused on problem-based treatment options for MF patients, discriminating in standard care and novel therapeutic approaches still under investigation. […] The considerable heterogeneity in clinical presentation and disease evolution results in widely variable patient outcomes, which are being captured with increasing accuracy by continuously evolving prognostic scoring systems.

• #2 Myelofibrosis – Watch and wait – Blood Cancer UK Online Community Forum

  https://forum.bloodcancer.org.uk/t/myelofibrosis/10197

  Myelofibrosis (MF) is a type of blood cancer that affects blood cell production in your bone marrow. […] Although the fatigue with these MPNs is often no joke and can even be disabling, being on watch and wait AKA active monitoring would be my ideal. Weirdly enough, active monitoring is considered treatment in that you likely don’t need any other invasive type of intervention yet while your blood cell numbers and bone marrow are observed over time. […] I’d be tempted to ask your haematologist about your care plan and what to expect going forwards in terms of what other treatments you might expect. […] Oh and another thing that might feel reassuring is searching this forum for others living with MF. There are many folks here who initially had Essential thrombocythemia (ET) or Polycythaemia vera (PV) which transformed into MF. […] I hope you continue to stay on watch and wait! […] I have been on a trial for 12 mths, my bloods are all back to normal even though my platelets were at 2000 now 375. […] I look forward to hearing more about you so please do keep posting.

• #2 Blood Treatments for Myeloproliferative Disorders | NYU Langone Health

  https://nyulangone.org/conditions/myeloproliferative-disorders/treatments/blood-treatments-for-myeloproliferative-disorders

  People with primary myelofibrosis who also have significant scarring of the bone marrow may need blood transfusions to restore and maintain healthy blood cell levels. […] Blood transfusions are given as an intravenous (IV) infusion through a catheter inserted into a vein in the arm. They can last for several hours and are used as often as once or twice a week. […] People with myelofibrosis may need psychological support, supportive care, and integrative health therapies to help them cope with ongoing blood transfusions. […] Perlmutter Cancer Center specialists provide care and support during treatment.

• #2 Key Patient Goals for Myelofibrosis Management

  https://www.oncnursingnews.com/view/key-patient-goals-for-myelofibrosis-management

  Key patient goals for managing myelofibrosis include improving quality of life by addressing low blood counts and constitutional symptoms, considering disease-modifying therapies and transplant to maximize longevity based on predicted survival, and incorporating personalized priorities through shared decision-making with their doctor when choosing treatments. […] Oncology nurses can help guide patients to the right supportive care for them.

• #3 Myelofibrosis (MF): Management of primary MF and secondary MF – UpToDate

  https://www.uptodate.com/contents/myelofibrosis-mf-management-of-primary-mf-and-secondary-mf

  Myelofibrosis (MF): Management of primary MF and secondary MF […] Primary myelofibrosis (PMF) and secondary myelofibrosis are BCR::ABL1-negative myeloproliferative neoplasms that cause bone marrow fibrosis and associated clinical findings. […] The goals of management of myelofibrosis are to relieve symptoms, prevent complications, and prolong survival. The prognosis is generally poor. […] Primary MF – PMF was previously called agnogenic myeloid metaplasia, myelofibrosis with myeloid metaplasia, and chronic idiopathic myelofibrosis. […] Secondary MF – Secondary MF refers to MF that evolves from either polycythemia vera (PV) or essential thrombocythemia (ET).

• #3 Identifying your Myelofibrosis Care Team

  https://www.mappingmf.com/charting-myelofibrosis/identifying-your-care-team/

  If you or someone you know has myelofibrosis (MF), getting the right care is key. MF symptoms can present and advance differently for everyone. Talk to your healthcare provider about any signs and symptoms you may be experiencing. Your healthcare provider can help refer you for the right testing and help you navigate potential treatment options. […] While your primary care physician or hematologist will often be taking the lead, it is common for your care team to include different specialists who are brought in based on your unique medical needs and symptom presentation. According to a poll of healthcare providers, 100% believe that collaboration across the extended oncology care team is essential. […] The caregiver is actually an important part of the care team. So it’s not simply the medical part of it. And of course, the patient is at the center of it. The caregiver actually is extremely important because it’s often the caregiver that when they come to the appointment that hears a lot of the information that might be missed by the patient, that can then provide a recap of what was said when they get home.

• #3 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  There have been tools developed to quantify patients symptoms and address them appropriately. […] Finally, Yacoub noted that patients are treated based on symptom burden and risk. […] Despite guidelines for these treatments, the time to progression in myelofibrosis varies with most experiencing progression in the first 10 years of a diagnosis. […] Long-term, progressive complications such as cytopenias, constitutional symptoms, organomegaly and extramedullary hematopoiesis have been reported, as well as short-term vascular events. […] There is also the potential for evolution to leukemia, which Yacoub noted makes the unmet need for patients who progress on JAK inhibitors of importance. […] Its important that, in addition to your clinical lab studies, symptoms are subjective and objective and its always important to communicate with your patients, Galinsky said.

• #3 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis interferes with the development of healthy blood cells and frequently causes anemia. When someone is anemic, they do not have enough red blood cells to carry oxygen throughout the body. This results in symptoms of fatigue, shortness of breath, feeling cold and looking pale. […] Regardless of the cause of anemia, your supportive care team will help you manage it. Therapies used include androgens, blood transfusions, corticosteroids, erythropoiesis stimulating agents and immunomodulators. In some cases, your doctor may recommend supplements to replace low levels of iron, folate or vitamin B12. […] Other therapies for anemia are being researched in clinical trials. Ask your doctor whether you may be a candidate for one. […] In the meantime, there are some actions you can take to ease the fatigue caused by the anemia. Tell your doctor if you are feeling weak and tired; get enough sleep; take a walk; eat a well-balanced diet; and perform activities that bring you joy.

• #3 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  What are some of the key reasons why patients may develop JAK inhibitor resistance or intolerance, and how do you address these problems in clinical practice? There are a variety of reasons why patients discontinue a JAK inhibitor, but these can be lumped into 2 categories: (1) the medication has not achieved, or is no longer achieving, treatment goals, or (2) adverse effects from the JAK inhibitor require discontinuation. In a large series of patients with myelofibrosis who were treated with ruxolitinib, about 60% of discontinuations were because of JAK inhibitor refractoriness/resistance, and around 40% were from adverse events. […] Resistance can arise from several mechanisms, including activation of alternative pathways and clonal evolution that are ongoing regardless of JAK inhibition. In clinical practice, we are addressing JAK inhibitor resistance through clinical trials of novel therapies, particularly in combination with JAK inhibitors, which can potentially mitigate resistance. New JAK inhibitors are also being developed that may more effectively target the overactive JAK-signal transducer and activator of transcription (STAT) pathway and reduce resistance.

• #3 Myelofibrosis, Cancer, Information, Resources

  https://www.cancercare.org/diagnosis/myelofibrosis

  Cancer Care provides free, professional support services for people affected by myelofibrosis, as well as myelofibrosis treatment information and financial help with cancer-related costs and treatment co-pays. […] Oncology social workers help you cope with the emotional and practical challenges of myelofibrosis. […] People coping with serious conditions may feel many strong emotions and its common to need extra support to help get through difficult times. Patients and family members can benefit from counseling. Cancer Care services include telephone and online support groups for people with cancer and their loved ones. […] Myelofibrosis is the rarest of the MPNs and this can make finding information and support more of a challenge. Fortunately, you dont have to travel that road alone, and there are a number of groups that can assist.

• #3 Treatment for Myeloproliferative Neoplasms (MPN) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/leukemias/treatment/treatment-myeloproliferative-neoplasms

  People with myelofibrosis often have anemia. This can be treated with blood transfusions. There are a variety of ways to treat anemia as well. These include the drugs danazol, thalidomide (Thalomid), and lenalidomide (Revlimid), as well as the hormone erythropoietin. […] Other drugs that treat myelofibrosis include interferon and hydroxyurea (Hydrea). […] The only potential cure for myelofibrosis is a bone marrow transplant. Not everyone with the disease is able to have this procedure. […] Some people with myelofibrosis develop acute myeloid leukemia. At MSK, we are committed to improving outcomes for people with myelofibrosis and people with acute myeloid leukemia that has developed after myelofibrosis. We are exploring new treatment options for people with these conditions and are working to translate new ideas from our research laboratories into innovative clinical trials.

• #3

  https://www.nni.com.sg/patient-care/conditions-treatments/myelofibrosis

  Myelofibrosis – Treatments […] Issues in patients with myelofibrosis include: […] AnaemiaTreatment for anaemia includes danazol, erythropoietin, immunomodulatory agents (iMiDs) and blood transfusion […] High blood counts: hydroxyurea, anagrelide, PEGylated interferon […] Enlarged spleen: JAK inhibitors (ruxolitinib), radiotherapy to the spleen, splenectomy […] Constitutional symptoms such as fatigue and night sweats: ruxolitinib […] For younger patients with advanced or poor risk myelofibrosis, allogeneic hematopoietic stem cell transplant may be a consideration because transplant is the only treatment that can potentially cure myelofibrosis. SGH has extensive expertise in treating MPNs. As the largest hospital in Singapore treating MPNs, it is a one stop comprehensive care centre with clinical and laboratory facilities for diagnosis and monitoring of treatment. We offer state of the art therapies with the possibility of participation in local and international clinical trials. Patients receive holistic care, individualized to their condition and preferences.

• #3

  https://www.cancernursingtoday.com/page/myelofibrosis

  Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients. […] Adding Navitoclax to Ruxolitinib Reduces Spleen Volume in Patients With Persistent or Progressive Myelofibrosis. […] Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable spleen volume reduction. […] Adding Low-Dose Total Body Irradiation to Fludarabine and Busulfan Reduces Graft Failure in Patients with Myelofibrosis. […] Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure. […] LCL161 in Treating Patients With Myelofibrosis: Phase II Trial Results. […] A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis.

• #3 A myelofibrosis survivor’s stem cell transplant advice | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/a-myelofibrosis-survivors-stem-cell-transplant-advice.h00-159149190.html

  Myelofibrosis is typically treated with a stem cell transplant, so I started working with Uday Popat, M.D., to find a donor. […] Luckily, I had two perfect unrelated matches through Be the Match, the National Marrow Donor Program. We scheduled the transplant for Feb. 3, 2016. I recovered quickly with very few side effects so I ended up leaving the hospital two weeks early. […] Preparing for a stem cell transplant is tough, so my advice to anyone facing one is to go in as strong as you can. Work out until the day you enter the hospital, and dont pass up the cherry pie. […] Recovering from a stem cell transplant is like a marathon, not a sprint.

• #3 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis […] The symptoms and side effects of myelofibrosis are unique to each person, making a personalized approach to managing them essential. As a result, you will work closely with a multidisciplinary health care team that will help you manage the disease so you can maintain a good quality of life. […] Your team will draw on a broad range of services known as palliative care or supportive care. Palliative care is often confused with hospice care, but palliative care services may be used at any time during the cancer care continuum, while hospice focuses on end-of-life care. […] Supportive care addresses the physical, emotional, practical, spiritual, financial and family-related challenges of people diagnosed with cancer and their loved ones. […] Supportive care often focuses on managing physical symptoms such as fatigue, weight loss, bone and joint pain, fever, rash, night sweats, gout, headaches, Graft-versus-Host Disease (GvHD), diarrhea, mouth sores, nausea and vomiting, and abdominal pain due to an enlarged liver or spleen.

• #3 Myelofibrosis: Self-Care Tips

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-self-care

  Myelofibrosis (a form of blood cancer) can be a long-term condition, but taking good care of yourself can help you enjoy a happier, healthier life. […] If myelofibrosis has pulled you away from work, your spirits may get a boost if you go back when you’re up to it. That can help you feel like you’re back to your normal life and get you out of the house and around other people. […] If you think fatigue or other effects of myelofibrosis could affect your work: Ask your boss if you can start part-time or work on a flexible schedule. Be patient with yourself as you build up your strength and mental focus. You might ask your doctor to write a letter explaining what myelofibrosis is and how it can affect you. […] Your medical team can help you get your weight in line.

• #3 Get Myelofibrosis Care | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelofibrosis-treatment

  Providers from different specialties come together as a care team that plans your treatment, keeps an eye on your progress and guides you through recovery and follow-up care. We build this team based on your unique needs and diagnosis. […] Our experts take the time to listen and answer your questions. We want to hear how myelofibrosis affects your life, so we can choose the best treatments ones that lessen your side effects, slow disease progression and help you keep doing the activities you love. […] This team stays with you throughout your diagnosis, treatment and beyond. They meet weekly to talk about your progress and adjust your treatment plan as needed. […] Your care team explores all options, including the latest clinical trials, as they craft the most personalized treatment plan. We dont just plan the medical side of things we also consider your goals and quality of life to be sure you get the latest treatment that focuses on you.

• #3 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Taking part in a clinical trial may be the best treatment choice for some myelofibrosis (MF) patients. Patient participation in clinical trials is important in the development of new and more effective treatments for MF and may provide patients with additional treatment options. […] Certain factors can affect a patients prognosis (a persons chance of recovery or the likely outcome of their disease). These are called prognostic factors, and they help doctors predict how a patients disease is likely to respond to treatment. These factors help doctors plan the most appropriate treatment for each patient. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers. It is important for patients and the members of their medical team to discuss all treatment options, including treatments being studied in clinical trials.

• #3 Considerations to comprehensive care for the older individual with myelofibrosis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/36333065/

  Over the last decade, we have witnessed a massive increase in available clinical agents, both in the clinical trial setting and following commercial use approval, directed to reduced life expectancy as well as the considerable symptom, splenic and anaemia burden associated with myelofibrosis. […] Given the median age of onset of the disease, coupled with an ageing population globally, we will be caring for an increasingly aged myelofibrosis cohort in future years. […] We will need to adapt our approach, emphasizing the holistic management of the older individual with myelofibrosis accordingly. […] Out with the pharmacological management of the disease, consideration needs to be given to interventions based on concurrent illness, comprehensive geriatric assessments, frailty, polypharmacy and drug-drug interactions, nutritional issues, psychological concerns (depression, anxiety or distress), cognitive decline and social/economic aspects. […] Within this review, we summarise available data addressing these issues, outline knowledge gaps and suggest a summative and holistic approach to the older individual with myelofibrosis.

• #3 Myelofibrosis: Follow-Up Care After Treatment

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-aftercare

  If youve been diagnosed with myelofibrosis, a kind of cancer that affects your blood, follow-up care can be almost as important as your initial treatment. […] Your medical team will want to keep a close eye on the number of red and white blood cells and platelets you have. You’ll also want to be on the lookout for any familiar symptoms of myelofibrosis, like anemia (when your body isn’t making enough red blood cells). […] Communication with your doctors during these visits is key. […] Sometimes life can be hard after treatment for cancer. You might feel depressed, anxious, or lonely. Survivorship is a newer form of follow-up care that can help support your emotional and mental health. […] A good survivorship plan should include: a treatment summary, a description of the follow-up appointments and tests you’ll need and how often, tips on self-care, an understanding of possible side effects of treatment and how to manage them, and ways you can address your physical and mental health.

• #3 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  How do you monitor for disease progression? I will discuss with patients how they are feeling in order to determine if there are any new or developing symptoms that could be a sign that their disease is progressing. I will also review their laboratory work looking for changes in blood counts that could be a signal of disease evolution. […] For instance, development of anemia or thrombocytopenia may signal worsening bone marrow function or progression to secondary acute leukemia. If there are concerning signs or symptoms, I will then perform a bone marrow biopsy with aspirate that will include assessment of mutations and chromosomal abnormalities to determine if their disease is progressing. […] What are the first-line treatment options for a patient newly diagnosed with myelofibrosis, and how do you determine the best course of action? For patients with myelofibrosis, the first-line treatment options include Janus kinase (JAK) inhibitors, which are effective at improving spleen size and reducing symptom burden. The US Food and Drug Administration (FDA) has approved 4 JAK inhibitors for the treatment of myelofibrosis: ruxolitinib, fedratinib, pacritinib, and momelotinib. In general, ruxolitinib is the first-line treatment option unless there is thrombocytopenia, in which case pacritinib is more appropriate. In patients with baseline anemia, momelotinib may be the best choice.

• #3 Patient Advocacy in Myelofibrosis Care

  https://www.pharmacytimes.com/view/patient-advocacy-in-myelofibrosis-care

  Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management. […] In this segment, Mahmoudjafari directs a discussion with Nachar on the crucial role patients play in advocating for themselves and improving access to myelofibrosis treatments. Nachar emphasizes the significance of patient education on navigating the health care system and accessing medications. […] The conversation highlights the pivotal role of pharmacists in advocating for patients during multidisciplinary discussions, considering socioeconomic factors, and ensuring appropriate therapy selection. […] The discussion underscores the collaborative and proactive approach pharmacists employ to enhance patient outcomes and quality of life.

• #3 Redefining Myelofibrosis Care: Treatment Advances & Key Considerations for Managed Care Professionals | PCE

  https://practicingclinicians.com/activities/oncology/myelofibrosis-care-1/33439

  Develop evidence-based second-line therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy. […] Assess the toxicity profiles of current and emerging MF therapies to collaboratively formulate an adverse event management plan that supports quality of life and continuation of treatment. […] Explain new data on emerging agents for MF to educate colleagues and counsel eligible patients regarding ongoing trial opportunities.

• #3 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  Patients with myelofibrosis have unique presentations and each patient has unique therapeutic needs that requires collaboration between the physician, the nurse, the nurse practitioner, that pharmacist the whole health care system to try to provide better care, Yacoub said. […] There is also a significant education need for practitioners, as well as the patients and their caregivers to teach them more about myelofibrosis, how to approach the disease, and [identify] the unmet needs so that we can work as a team to advance the field. […] The best avenue for the management of patients with myelofibrosis can evolve over time, Yacoub said, but noted that 3 goals are commonreduce splenomegaly, improve symptoms, and improve survival. […] This is a unique feature of MPNs which requires extra attention and examination by providers, Yacoub said.

• #3 ASH 2024 Symposia on MF Care – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/ash-24-peerview-mf-session-coverage

  Myelofibrosis treatment has expanded significantly in the past decade, especially with the approval of four JAK inhibitors. […] HSCT remains a cornerstone for patients with intermediate-1 or higher risk, offering long-term survival advantages. […] Anemia is a common and serious complication in myelofibrosis, often requiring transfusions. Reducing transfusion dependence is a key treatment goal. […] Patients who dont respond to JAK inhibitors may need alternative approaches. […] The session highlighted updates from the NCCN, including newer guidelines for stem cell transplants in MF. For older patients or those who dont qualify for HSCT, alternative treatments like JAK inhibitors remain essential. […] This session emphasized that myelofibrosis care is about more than just medicationsits about developing a holistic and personalized treatment plan.

• #3 Myelofibrosis – Care at Mayo Clinic – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelofibrosis/care-at-mayo-clinic/mac-20355065

  Mayo Clinic doctors draw on their experience caring for people with myelofibrosis to provide you with a personalized treatment plan. The experts at Mayo Clinic Comprehensive Cancer Center work together to provide you with the exact care you need. […] At Mayo Clinic, hematologists and transplant specialists work as a multidisciplinary team to care for people with myelofibrosis. Other doctors and healthcare professionals are included as needed. […] People with myelofibrosis who seek care at Mayo Clinic have access to clinical trials based on the latest treatment advances. […] Mayo Clinic doctors will work with you to review all of your treatment options and choose the treatment that best suits your needs and goals. The range of treatments offered to people with myelofibrosis includes medicines, blood transfusions, chemotherapy, targeted therapy, surgery to remove the spleen (splenectomy) and bone marrow transplant.

• #3 Myelofibrosis – Watch and wait – Blood Cancer UK Online Community Forum

  https://forum.bloodcancer.org.uk/t/myelofibrosis/10197

  Myelofibrosis (MF) is a type of blood cancer that affects blood cell production in your bone marrow. […] Although the fatigue with these MPNs is often no joke and can even be disabling, being on watch and wait AKA active monitoring would be my ideal. Weirdly enough, active monitoring is considered treatment in that you likely don’t need any other invasive type of intervention yet while your blood cell numbers and bone marrow are observed over time. […] I’d be tempted to ask your haematologist about your care plan and what to expect going forwards in terms of what other treatments you might expect. […] Oh and another thing that might feel reassuring is searching this forum for others living with MF. There are many folks here who initially had Essential thrombocythemia (ET) or Polycythaemia vera (PV) which transformed into MF. […] I hope you continue to stay on watch and wait! […] I have been on a trial for 12 mths, my bloods are all back to normal even though my platelets were at 2000 now 375. […] I look forward to hearing more about you so please do keep posting.

• #3 ASH 2024 Symposia on MF Care – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/ash-24-peerview-mf-session-coverage

  While managing myelofibrosis requires a great deal of care and consideration, the ongoing dedication to research and innovation provides hope for better outcomes. […] New data, evolving guidelines, and innovative therapies pave the way for a brighter future. Patients and caregivers are encouraged to stay informed, advocate for personalized care, and consider clinical trials when possible. […] By understanding the nuances of myelofibrosis treatment shared during this session, patients and caregivers can better engage with their healthcare teams and make informed decisions about their care.

• #4 Myelofibrosis: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000531.htm

  Myelofibrosis is a disorder of the bone marrow in which the marrow is replaced by fibrous scar tissue. […] Your health care provider will perform a physical exam and ask about your symptoms. […] Bone marrow or stem cell transplant may improve symptoms, and may cure the disease. This treatment is usually considered for younger people. […] Make an appointment with your provider if you have symptoms of this disorder. Seek medical care right away for uncontrolled bleeding, shortness of breath, or jaundice (yellow skin and whites of the eyes) that gets worse.

• #4 Identifying your Myelofibrosis Care Team

  https://www.mappingmf.com/charting-myelofibrosis/identifying-your-care-team/

  Based on the varying symptoms and presentations of the disease, an MF care team is often made up of specialists, including, but not limited to: Primary Doctor, Hematologist, Hematologist Oncologist, Nurse Practitioner, Social Worker. […] When identifying the members of your care team, you may want to consider seeking out a hematologist who specializes in MPNs.

• #4 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  My take-home message is always, always look at the patient. Always look at their labs, but always talk to the patientwhat are they reporting that their symptoms are? […] If their numbers are changing and theyre not feeling well, always ask if they are taking their drug. If they are not taking their drugwhy? If they are having adverse effects [AEs], its our job to help them [manage the symptoms]. […] The biggest thing is symptom management for these patients, reductions of complications, reducing the risk of thrombus, Ligon said. […] [We also must] make sure that these patients know that when they take hydroxyurea that they are wearing gloves when they administer the medication because they can cause toxicities through the skin.

• #4 Standard care and investigational drugs in the treatment of myelofibrosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6788389/

  Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly, constitutional symptoms, ineffective hematopoiesis, and an increased risk of leukemic transformation. […] Current therapeutic interventions are only partially effective with only allogeneic stem cell transplant potentially curative. […] Drug discontinuation is associated with a dismal outcome. […] Currently, there are no US Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved drugs for the treatment of anemia, with or without red blood cell (RBC) transfusion dependence, and thrombocytopenia in MF, but commonly used drugs include corticosteroids, androgenic steroids, erythropoietin, and immunomodulatory drugs (such as thalidomide, lenalidomide, and pomalidomide). […] Furthermore, given the detrimental effects of anemia and transfusion-related iron overload, a proper iron chelation therapy is crucial and seems to be effective on outcome of disease, in particular in terms of hematologic improvement and survival.

• #4 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  Although these agents are effective in reducing spleen size and improving symptoms, they do not affect disease progression. Therefore, I also evaluate all patients for allogeneic stem cell transplantation, which is the only curative modality. Appropriate patients are younger than age 75, with a low comorbidity burden and either intermediate-2 or high-risk disease. In addition, patients who do not respond to frontline JAK inhibitors should be considered for this approach. In patients who are transplant candidates, I will concurrently have them evaluated and start the process of finding a donor while initiating a JAK inhibitor. […] What are the most common adverse effects of JAK inhibitors, and how do you help patients manage these issues? There are short- and long-term effects of JAK inhibitors. Focusing on ruxolitinib, the most frequently used JAK inhibitor, patients can experience bruising, dizziness, and headaches, which generally resolves within a few weeks. Notable longer-term adverse events of ruxolitinib include increased rates of shingles infection, so I encourage my patients to get vaccinated for shingles before initiation. Weight gain has also been reported with ruxolitinib, but not with other JAK inhibitors. The other main adverse effect of ruxolitinib is worsening anemia and thrombocythemia, so I closely monitor blood counts during treatment.

• #4 Myelofibrosis: Follow-Up Care After Treatment

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-aftercare

  If youve been diagnosed with myelofibrosis, a kind of cancer that affects your blood, follow-up care can be almost as important as your initial treatment. […] Your medical team will want to keep a close eye on the number of red and white blood cells and platelets you have. You’ll also want to be on the lookout for any familiar symptoms of myelofibrosis, like anemia (when your body isn’t making enough red blood cells). […] Communication with your doctors during these visits is key. […] Sometimes life can be hard after treatment for cancer. You might feel depressed, anxious, or lonely. Survivorship is a newer form of follow-up care that can help support your emotional and mental health. […] A good survivorship plan should include: a treatment summary, a description of the follow-up appointments and tests you’ll need and how often, tips on self-care, an understanding of possible side effects of treatment and how to manage them, and ways you can address your physical and mental health.

• #4 Myelofibrosis (MF) – Leukaemia Care

  https://www.leukaemiacare.org.uk/support-and-information/information-about-blood-cancer/blood-cancer-information/about-myeloproliferative-neoplasms-mpn/myelofibrosis-mf/

  Most current treatments aim to control MF rather than cure it. They often work by improving levels of blood cells. […] Your haematology team may recommend a single treatment or a combination of treatments. They may also offer you treatments to manage other problems caused by your MF. […] This is called supportive treatment. It includes medicines to treat or prevent: Symptoms of MF, Complications of MF, Side effects of treatment for MF. […] If you are symptom-free and have lower-risk MF, its often better to wait to start treatment. You can still have treatment later, when you need it. […] Your consultant is the best person to advise you on your outlook. They can take account of your individual circumstances and test results. […] Remember that your risk group helps your haematology team look after you. It helps them plan and offer you the best treatment for your situation.

• #4 Myelofibrosis: Treatment Planning and Management

  https://www.onclive.com/view/myelofibrosis-treatment-planning-and-management

  What is the best approach for monitoring response to therapy? For every patient I see, I obtain a CBC [complete blood count], a symptom assessment at every visit, and possibly a radiological assessment of their spleen size every few months. This is crucial. We want to keep track of how the patient is doing in terms of their symptoms and also take a look at their blood counts to see if they are having any signs of progression, stability, or adverse events from their treatments. In the event one were to see, for example, a drop in platelet count or hemoglobin level, or a rise in white blood cell count, or an increase or new emergence of peripheral blood blasts, or for example, in the event of having worsening splenomegaly or new symptoms that emerge on stable doses of JAK inhibitors, one may be worried about a potential resistance or relapse/refractoriness to therapy. That is when the consideration for switching therapy to something else comes about. That something else could be in the form of hypomethylating agents or intensive chemotherapy, should the patient have had a definite progression of their underlying myelofibrosis, or to an alternative JAK inhibitor.

• #4

  https://www.cancernursingtoday.com/page/myelofibrosis

  Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients. […] Adding Navitoclax to Ruxolitinib Reduces Spleen Volume in Patients With Persistent or Progressive Myelofibrosis. […] Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable spleen volume reduction. […] Adding Low-Dose Total Body Irradiation to Fludarabine and Busulfan Reduces Graft Failure in Patients with Myelofibrosis. […] Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure. […] LCL161 in Treating Patients With Myelofibrosis: Phase II Trial Results. […] A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis.

• #4 Myelofibrosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelofibrosis/diagnosis-treatment/drc-20355062

  Our caring team of Mayo Clinic experts can help you with your myelofibrosis-related health concerns […] Palliative care is a special type of healthcare that helps people with serious illnesses feel better. If you have cancer, palliative care can help relieve pain and other symptoms. A team of healthcare professionals gives palliative care. This can include doctors, nurses and other specially trained health professionals. Their goal is to improve quality of life for you and your family. […] When palliative care is used along with all of the other treatments, people with cancer may feel better and live longer.

• #4 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis interferes with the development of healthy blood cells and frequently causes anemia. When someone is anemic, they do not have enough red blood cells to carry oxygen throughout the body. This results in symptoms of fatigue, shortness of breath, feeling cold and looking pale. […] Regardless of the cause of anemia, your supportive care team will help you manage it. Therapies used include androgens, blood transfusions, corticosteroids, erythropoiesis stimulating agents and immunomodulators. In some cases, your doctor may recommend supplements to replace low levels of iron, folate or vitamin B12. […] Other therapies for anemia are being researched in clinical trials. Ask your doctor whether you may be a candidate for one. […] In the meantime, there are some actions you can take to ease the fatigue caused by the anemia. Tell your doctor if you are feeling weak and tired; get enough sleep; take a walk; eat a well-balanced diet; and perform activities that bring you joy.

• #4 Myelofibrosis (MF) | Cancer Support Community

  https://www.cancersupportcommunity.org/myelofibrosis-mf

  Find educational resources and tips to cope with myelofibrosis (MF). This rare blood disease develops when the bone marrow makes too many blood cells. […] Check out this article about caregiving for a loved one with myelofibrosis. […] Check out this article about coping with myelofibrosis. […] Check out this article about managing symptoms of myelofibrosis. […] Check out this webpage with information about myelofibrosis. […] Learn more about MF using this resource. […] Watch this short video about the treatment options for myelofibrosis.

• #4 Patient-Centered Care in Myelofibrosis: Managing Expectations and Quality-of-Life Outcomes

  https://www.targetedonc.com/view/patient-centered-care-in-myelofibrosis-managing-expectations-and-quality-of-life-outcomes

  Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and careful attention to patient goals and expectations. […] The American Society of Clinical Oncology and the Community Oncology Alliance released new Oncology Medical Home standards that are designed to help guide care providers as they treat patients.

• #4 Key Patient Goals for Myelofibrosis Management

  https://www.oncnursingnews.com/view/key-patient-goals-for-myelofibrosis-management

  Key patient goals for managing myelofibrosis include improving quality of life by addressing low blood counts and constitutional symptoms, considering disease-modifying therapies and transplant to maximize longevity based on predicted survival, and incorporating personalized priorities through shared decision-making with their doctor when choosing treatments. […] Oncology nurses can help guide patients to the right supportive care for them.

• #4 Myeloproliferative Neoplasms | Mays Cancer Center

  https://cancer.uthscsa.edu/cancer-care/types-and-treatments/myeloproliferative-neoplasms

  Myelofibrosis: Abnormal blood cells build up in the bone marrow and cause scar tissue. […] Treatment for myeloproliferative neoplasms often includes chemotherapy, which uses cancer drugs to disrupt abnormal cell growth. We are also experienced in delivering innovative treatments, such as targeted therapy. This option attacks specific proteins within cancer cells for more precise care, often with fewer or milder side effects. […] We tailor therapies to help older adults receive safe, effective care. Patients may receive smaller doses of medications, adjustments to accommodate other medical conditions and extra support.

• #4 Get Myelofibrosis Care | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelofibrosis-treatment

  If your symptoms are getting in the way of your quality of life, your provider may recommend palliative care. You get a support network of providers experienced in helping you navigate your diagnosis and treatment physically, mentally, emotionally and spiritually. […] Once treatment is done, youll move to the next phase follow-up care. This means youll have regular visits with your care team and do tests to make sure the cancer hasnt come back. Staying in touch with your providers like this means that we can catch a recurrence early and quickly start treatment.

• #4 Myelofibrosis (MF) – Leukaemia Care

  https://www.leukaemiacare.org.uk/support-and-information/information-about-blood-cancer/blood-cancer-information/about-myeloproliferative-neoplasms-mpn/myelofibrosis-mf/

  Myelofibrosis (MF) is a slow-growing blood cancer that causes scarring in your bone marrow. This stops it from making enough healthy blood cells. Treatment for MF aims to manage symptoms and other health problems that can develop over time, such as anaemia and a swollen spleen. […] Most people who need treatment for MF take tablets called JAK inhibitors. Other options include oral chemotherapy or peginterferon injections. […] You may also need treatments to prevent or manage complications of MF. […] Your haematology team will regularly check you for signs and symptoms of transformation. If it happens, you will need treatment for AML. […] Your doctor will regularly monitor your MF and offer you treatment if you need it. Not everyone needs treatment straight away. If you are in a lower MF risk group, you may be on active monitoring instead.

• #4 Tailoring Myelofibrosis Care: Patient Preferences and Challenges

  https://www.pharmacytimes.com/view/tailoring-myelofibrosis-care-patient-preferences-and-challenges

  Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration. […] Griffin emphasizes the pharmacists role in symptom management, using tools like the Myeloproliferative Neoplasm Symptom Assessment Form, and highlights the importance of identifying and addressing specific symptoms that matter most to each patient. […] He underscores the flexibility provided by the array of available therapies, enabling tailored approaches beyond conventional options. […] Mancini acknowledges the progress made in integrating pharmacists into oncology care teams but notes challenges related to new roles and managing mail order complexities. […] He emphasizes the importance of persistently demonstrating value, even if not every recommendation is accepted, and highlights ongoing battles with insurance and mail order issues. […] The discussion reveals opportunities for pharmacists in tailoring therapies and navigating challenges in collaborative care for myelofibrosis patients.

• #4 Redefining Myelofibrosis Care: Treatment Advances & Key Considerations for Managed Care Professionals | PCE

  https://practicingclinicians.com/activities/oncology/myelofibrosis-care-1/33439

  Develop evidence-based second-line therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy. […] Assess the toxicity profiles of current and emerging MF therapies to collaboratively formulate an adverse event management plan that supports quality of life and continuation of treatment. […] Explain new data on emerging agents for MF to educate colleagues and counsel eligible patients regarding ongoing trial opportunities.

• #4 What Is Myelofibrosis (MF)? | Primary Myelofibrosis

  https://www.voicesofmpn.com/myelofibrosis-information

  Don’t be afraid to talk to your doctor. You have to be proactive. You need to inform them what’s going on in your life. You need to tell them how you’re feeling. […] To try to help control the signs and symptoms of MF, Healthcare Professionals use therapies such as blood transfusions, radiation, removal of the spleen, and stem cell transplantation. People with MF may be prescribed other treatments, including but not limited to chemotherapy drugs. […] Regular monitoring and medical supervision can help identify signs of disease progression and help minimize the risk of complications. […] When you’re living with MF, you may find yourself saying that you’re fine even when you might not be. But when you don’t speak up and share how you really feel, you may miss out on the opportunity to get the care and support that you need and deserve. […] Remember, changes in your MF symptoms could be a sign that your MF is changing, too. So be sure to spell out how you really feel. Because fine is not enough.

• #4 ASH 2024 Symposia on MF Care – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/ash-24-peerview-mf-session-coverage

  Myelofibrosis treatment has expanded significantly in the past decade, especially with the approval of four JAK inhibitors. […] HSCT remains a cornerstone for patients with intermediate-1 or higher risk, offering long-term survival advantages. […] Anemia is a common and serious complication in myelofibrosis, often requiring transfusions. Reducing transfusion dependence is a key treatment goal. […] Patients who dont respond to JAK inhibitors may need alternative approaches. […] The session highlighted updates from the NCCN, including newer guidelines for stem cell transplants in MF. For older patients or those who dont qualify for HSCT, alternative treatments like JAK inhibitors remain essential. […] This session emphasized that myelofibrosis care is about more than just medicationsits about developing a holistic and personalized treatment plan.

• #4 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Taking part in a clinical trial may be the best treatment choice for some myelofibrosis (MF) patients. Patient participation in clinical trials is important in the development of new and more effective treatments for MF and may provide patients with additional treatment options. […] Certain factors can affect a patients prognosis (a persons chance of recovery or the likely outcome of their disease). These are called prognostic factors, and they help doctors predict how a patients disease is likely to respond to treatment. These factors help doctors plan the most appropriate treatment for each patient. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers. It is important for patients and the members of their medical team to discuss all treatment options, including treatments being studied in clinical trials.

• #4 Blood Treatments for Myeloproliferative Disorders | NYU Langone Health

  https://nyulangone.org/conditions/myeloproliferative-disorders/treatments/blood-treatments-for-myeloproliferative-disorders

  People with primary myelofibrosis who also have significant scarring of the bone marrow may need blood transfusions to restore and maintain healthy blood cell levels. […] Blood transfusions are given as an intravenous (IV) infusion through a catheter inserted into a vein in the arm. They can last for several hours and are used as often as once or twice a week. […] People with myelofibrosis may need psychological support, supportive care, and integrative health therapies to help them cope with ongoing blood transfusions. […] Perlmutter Cancer Center specialists provide care and support during treatment.

• #5 Myelofibrosis | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/myelofibrosis

  Myelofibrosis sometimes happens on its own. This is called primary myelofibrosis. […] Some people with myelofibrosis have no symptoms and might not need treatment right away. Others with more-serious forms of the disease might need treatment. Treatment for myelofibrosis typically focuses on relieving symptoms. […] The goal of treatment for most people with myelofibrosis is to provide relief from symptoms of the disease. For some, a bone marrow transplant, also called a stem cell transplant, may provide a chance for a cure. […] Palliative care is a special type of healthcare that helps people with serious illnesses feel better. If you have cancer, palliative care can help relieve pain and other symptoms. […] When palliative care is used along with all of the other treatments, people with cancer may feel better and live longer.

• #5 Identifying your Myelofibrosis Care Team

  https://www.mappingmf.com/charting-myelofibrosis/identifying-your-care-team/

  If you or someone you know has myelofibrosis (MF), getting the right care is key. MF symptoms can present and advance differently for everyone. Talk to your healthcare provider about any signs and symptoms you may be experiencing. Your healthcare provider can help refer you for the right testing and help you navigate potential treatment options. […] While your primary care physician or hematologist will often be taking the lead, it is common for your care team to include different specialists who are brought in based on your unique medical needs and symptom presentation. According to a poll of healthcare providers, 100% believe that collaboration across the extended oncology care team is essential. […] The caregiver is actually an important part of the care team. So it’s not simply the medical part of it. And of course, the patient is at the center of it. The caregiver actually is extremely important because it’s often the caregiver that when they come to the appointment that hears a lot of the information that might be missed by the patient, that can then provide a recap of what was said when they get home.

• #5 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  What are some of the key reasons why patients may develop JAK inhibitor resistance or intolerance, and how do you address these problems in clinical practice? There are a variety of reasons why patients discontinue a JAK inhibitor, but these can be lumped into 2 categories: (1) the medication has not achieved, or is no longer achieving, treatment goals, or (2) adverse effects from the JAK inhibitor require discontinuation. In a large series of patients with myelofibrosis who were treated with ruxolitinib, about 60% of discontinuations were because of JAK inhibitor refractoriness/resistance, and around 40% were from adverse events. […] Resistance can arise from several mechanisms, including activation of alternative pathways and clonal evolution that are ongoing regardless of JAK inhibition. In clinical practice, we are addressing JAK inhibitor resistance through clinical trials of novel therapies, particularly in combination with JAK inhibitors, which can potentially mitigate resistance. New JAK inhibitors are also being developed that may more effectively target the overactive JAK-signal transducer and activator of transcription (STAT) pathway and reduce resistance.

• #5 What Is Myelofibrosis (MF)? | Primary Myelofibrosis

  https://www.voicesofmpn.com/myelofibrosis-information

  Don’t be afraid to talk to your doctor. You have to be proactive. You need to inform them what’s going on in your life. You need to tell them how you’re feeling. […] To try to help control the signs and symptoms of MF, Healthcare Professionals use therapies such as blood transfusions, radiation, removal of the spleen, and stem cell transplantation. People with MF may be prescribed other treatments, including but not limited to chemotherapy drugs. […] Regular monitoring and medical supervision can help identify signs of disease progression and help minimize the risk of complications. […] When you’re living with MF, you may find yourself saying that you’re fine even when you might not be. But when you don’t speak up and share how you really feel, you may miss out on the opportunity to get the care and support that you need and deserve. […] Remember, changes in your MF symptoms could be a sign that your MF is changing, too. So be sure to spell out how you really feel. Because fine is not enough.

• #5 A myelofibrosis survivor’s stem cell transplant advice | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/a-myelofibrosis-survivors-stem-cell-transplant-advice.h00-159149190.html

  Myelofibrosis is typically treated with a stem cell transplant, so I started working with Uday Popat, M.D., to find a donor. […] Luckily, I had two perfect unrelated matches through Be the Match, the National Marrow Donor Program. We scheduled the transplant for Feb. 3, 2016. I recovered quickly with very few side effects so I ended up leaving the hospital two weeks early. […] Preparing for a stem cell transplant is tough, so my advice to anyone facing one is to go in as strong as you can. Work out until the day you enter the hospital, and dont pass up the cherry pie. […] Recovering from a stem cell transplant is like a marathon, not a sprint.

• #5 Myelofibrosis: Self-Care Tips

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-self-care

  Myelofibrosis (a form of blood cancer) can be a long-term condition, but taking good care of yourself can help you enjoy a happier, healthier life. […] If myelofibrosis has pulled you away from work, your spirits may get a boost if you go back when you’re up to it. That can help you feel like you’re back to your normal life and get you out of the house and around other people. […] If you think fatigue or other effects of myelofibrosis could affect your work: Ask your boss if you can start part-time or work on a flexible schedule. Be patient with yourself as you build up your strength and mental focus. You might ask your doctor to write a letter explaining what myelofibrosis is and how it can affect you. […] Your medical team can help you get your weight in line.

• #5 Myelofibrosis, Cancer, Information, Resources

  https://www.cancercare.org/diagnosis/myelofibrosis

  Cancer Care provides free, professional support services for people affected by myelofibrosis, as well as myelofibrosis treatment information and financial help with cancer-related costs and treatment co-pays. […] Oncology social workers help you cope with the emotional and practical challenges of myelofibrosis. […] People coping with serious conditions may feel many strong emotions and its common to need extra support to help get through difficult times. Patients and family members can benefit from counseling. Cancer Care services include telephone and online support groups for people with cancer and their loved ones. […] Myelofibrosis is the rarest of the MPNs and this can make finding information and support more of a challenge. Fortunately, you dont have to travel that road alone, and there are a number of groups that can assist.

• #5 Get Myelofibrosis Care | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelofibrosis-treatment

  Providers from different specialties come together as a care team that plans your treatment, keeps an eye on your progress and guides you through recovery and follow-up care. We build this team based on your unique needs and diagnosis. […] Our experts take the time to listen and answer your questions. We want to hear how myelofibrosis affects your life, so we can choose the best treatments ones that lessen your side effects, slow disease progression and help you keep doing the activities you love. […] This team stays with you throughout your diagnosis, treatment and beyond. They meet weekly to talk about your progress and adjust your treatment plan as needed. […] Your care team explores all options, including the latest clinical trials, as they craft the most personalized treatment plan. We dont just plan the medical side of things we also consider your goals and quality of life to be sure you get the latest treatment that focuses on you.

• #5 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment

  Taking part in a clinical trial may be the best treatment choice for some myelofibrosis (MF) patients. Patient participation in clinical trials is important in the development of new and more effective treatments for MF and may provide patients with additional treatment options. […] Certain factors can affect a patients prognosis (a persons chance of recovery or the likely outcome of their disease). These are called prognostic factors, and they help doctors predict how a patients disease is likely to respond to treatment. These factors help doctors plan the most appropriate treatment for each patient. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers. It is important for patients and the members of their medical team to discuss all treatment options, including treatments being studied in clinical trials.

• #5 Myeloproliferative Neoplasms | Mays Cancer Center

  https://cancer.uthscsa.edu/cancer-care/types-and-treatments/myeloproliferative-neoplasms

  Myelofibrosis: Abnormal blood cells build up in the bone marrow and cause scar tissue. […] Treatment for myeloproliferative neoplasms often includes chemotherapy, which uses cancer drugs to disrupt abnormal cell growth. We are also experienced in delivering innovative treatments, such as targeted therapy. This option attacks specific proteins within cancer cells for more precise care, often with fewer or milder side effects. […] We tailor therapies to help older adults receive safe, effective care. Patients may receive smaller doses of medications, adjustments to accommodate other medical conditions and extra support.

• #5 Myelofibrosis: Follow-Up Care After Treatment

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-aftercare

  If youve been diagnosed with myelofibrosis, a kind of cancer that affects your blood, follow-up care can be almost as important as your initial treatment. […] Your medical team will want to keep a close eye on the number of red and white blood cells and platelets you have. You’ll also want to be on the lookout for any familiar symptoms of myelofibrosis, like anemia (when your body isn’t making enough red blood cells). […] Communication with your doctors during these visits is key. […] Sometimes life can be hard after treatment for cancer. You might feel depressed, anxious, or lonely. Survivorship is a newer form of follow-up care that can help support your emotional and mental health. […] A good survivorship plan should include: a treatment summary, a description of the follow-up appointments and tests you’ll need and how often, tips on self-care, an understanding of possible side effects of treatment and how to manage them, and ways you can address your physical and mental health.

• #5 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  How do you monitor for disease progression? I will discuss with patients how they are feeling in order to determine if there are any new or developing symptoms that could be a sign that their disease is progressing. I will also review their laboratory work looking for changes in blood counts that could be a signal of disease evolution. […] For instance, development of anemia or thrombocytopenia may signal worsening bone marrow function or progression to secondary acute leukemia. If there are concerning signs or symptoms, I will then perform a bone marrow biopsy with aspirate that will include assessment of mutations and chromosomal abnormalities to determine if their disease is progressing. […] What are the first-line treatment options for a patient newly diagnosed with myelofibrosis, and how do you determine the best course of action? For patients with myelofibrosis, the first-line treatment options include Janus kinase (JAK) inhibitors, which are effective at improving spleen size and reducing symptom burden. The US Food and Drug Administration (FDA) has approved 4 JAK inhibitors for the treatment of myelofibrosis: ruxolitinib, fedratinib, pacritinib, and momelotinib. In general, ruxolitinib is the first-line treatment option unless there is thrombocytopenia, in which case pacritinib is more appropriate. In patients with baseline anemia, momelotinib may be the best choice.

• #5 Myelofibrosis (MF) – Leukaemia Care

  https://www.leukaemiacare.org.uk/support-and-information/information-about-blood-cancer/blood-cancer-information/about-myeloproliferative-neoplasms-mpn/myelofibrosis-mf/

  Myelofibrosis (MF) is a slow-growing blood cancer that causes scarring in your bone marrow. This stops it from making enough healthy blood cells. Treatment for MF aims to manage symptoms and other health problems that can develop over time, such as anaemia and a swollen spleen. […] Most people who need treatment for MF take tablets called JAK inhibitors. Other options include oral chemotherapy or peginterferon injections. […] You may also need treatments to prevent or manage complications of MF. […] Your haematology team will regularly check you for signs and symptoms of transformation. If it happens, you will need treatment for AML. […] Your doctor will regularly monitor your MF and offer you treatment if you need it. Not everyone needs treatment straight away. If you are in a lower MF risk group, you may be on active monitoring instead.

• #5 Tailoring Myelofibrosis Care: Patient Preferences and Challenges

  https://www.pharmacytimes.com/view/tailoring-myelofibrosis-care-patient-preferences-and-challenges

  Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration. […] Griffin emphasizes the pharmacists role in symptom management, using tools like the Myeloproliferative Neoplasm Symptom Assessment Form, and highlights the importance of identifying and addressing specific symptoms that matter most to each patient. […] He underscores the flexibility provided by the array of available therapies, enabling tailored approaches beyond conventional options. […] Mancini acknowledges the progress made in integrating pharmacists into oncology care teams but notes challenges related to new roles and managing mail order complexities. […] He emphasizes the importance of persistently demonstrating value, even if not every recommendation is accepted, and highlights ongoing battles with insurance and mail order issues. […] The discussion reveals opportunities for pharmacists in tailoring therapies and navigating challenges in collaborative care for myelofibrosis patients.

• #5 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  Although these agents are effective in reducing spleen size and improving symptoms, they do not affect disease progression. Therefore, I also evaluate all patients for allogeneic stem cell transplantation, which is the only curative modality. Appropriate patients are younger than age 75, with a low comorbidity burden and either intermediate-2 or high-risk disease. In addition, patients who do not respond to frontline JAK inhibitors should be considered for this approach. In patients who are transplant candidates, I will concurrently have them evaluated and start the process of finding a donor while initiating a JAK inhibitor. […] What are the most common adverse effects of JAK inhibitors, and how do you help patients manage these issues? There are short- and long-term effects of JAK inhibitors. Focusing on ruxolitinib, the most frequently used JAK inhibitor, patients can experience bruising, dizziness, and headaches, which generally resolves within a few weeks. Notable longer-term adverse events of ruxolitinib include increased rates of shingles infection, so I encourage my patients to get vaccinated for shingles before initiation. Weight gain has also been reported with ruxolitinib, but not with other JAK inhibitors. The other main adverse effect of ruxolitinib is worsening anemia and thrombocythemia, so I closely monitor blood counts during treatment.

• #5 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  Patients with myelofibrosis have unique presentations and each patient has unique therapeutic needs that requires collaboration between the physician, the nurse, the nurse practitioner, that pharmacist the whole health care system to try to provide better care, Yacoub said. […] There is also a significant education need for practitioners, as well as the patients and their caregivers to teach them more about myelofibrosis, how to approach the disease, and [identify] the unmet needs so that we can work as a team to advance the field. […] The best avenue for the management of patients with myelofibrosis can evolve over time, Yacoub said, but noted that 3 goals are commonreduce splenomegaly, improve symptoms, and improve survival. […] This is a unique feature of MPNs which requires extra attention and examination by providers, Yacoub said.

• #5

  https://www.cancernursingtoday.com/page/myelofibrosis

  Learn more about the newest discoveries and latest clinical insights in myelofibrosis (MF). […] Cancer Nursing Today provides up-to-date perspectives and information on transplant trends in MF, novel therapeutic targets, and more. […] From promising new treatments to risk factors and prognostics, explore the latest developments in MF care. […] Anemia Support in Myelofibrosis: Dr. Bose Discusses Results of JUMP Trial Analysis. […] Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib. […] Higher Baseline Quality of Life Linked to Longer Overall Survival in Myelofibrosis. […] Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis. […] Pacritinib More Effective Than Best Available Treatment for Myelofibrosis and Severe Thrombocytopenia.

• #5 ASH 2024 Symposia on MF Care – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/ash-24-peerview-mf-session-coverage

  While managing myelofibrosis requires a great deal of care and consideration, the ongoing dedication to research and innovation provides hope for better outcomes. […] New data, evolving guidelines, and innovative therapies pave the way for a brighter future. Patients and caregivers are encouraged to stay informed, advocate for personalized care, and consider clinical trials when possible. […] By understanding the nuances of myelofibrosis treatment shared during this session, patients and caregivers can better engage with their healthcare teams and make informed decisions about their care.

• #6 Myelofibrosis: Symptoms, Types, Prognosis & Treatment

  https://my.clevelandclinic.org/health/diseases/15672-myelofibrosis

  Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. Treatment goals mainly involve managing symptoms and conditions that arise, including anemia and an enlarged spleen. […] You dont need treatment unless youre experiencing symptoms. Still, your healthcare provider will monitor your condition even if you dont require immediate treatment. […] For most people, treatment goals are to manage conditions associated with myelofibrosis, including anemia and splenomegaly. […] Treatments can help manage symptoms that may be interfering with your day-to-day life. In the meantime, ask your provider to connect you with resources that can help you navigate the changes you may be experiencing. Palliative care and support groups are useful options when adjusting to a cancer diagnosis.

• #6 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  My take-home message is always, always look at the patient. Always look at their labs, but always talk to the patientwhat are they reporting that their symptoms are? […] If their numbers are changing and theyre not feeling well, always ask if they are taking their drug. If they are not taking their drugwhy? If they are having adverse effects [AEs], its our job to help them [manage the symptoms]. […] The biggest thing is symptom management for these patients, reductions of complications, reducing the risk of thrombus, Ligon said. […] [We also must] make sure that these patients know that when they take hydroxyurea that they are wearing gloves when they administer the medication because they can cause toxicities through the skin.

• #6 Patient-Centered Care in Myelofibrosis: Managing Expectations and Quality-of-Life Outcomes

  https://www.targetedonc.com/view/patient-centered-care-in-myelofibrosis-managing-expectations-and-quality-of-life-outcomes

  Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and careful attention to patient goals and expectations. […] The American Society of Clinical Oncology and the Community Oncology Alliance released new Oncology Medical Home standards that are designed to help guide care providers as they treat patients.

• #6 Myelofibrosis: Self-Care Tips

  https://www.webmd.com/cancer/lymphoma/myelofibrosis-self-care

  Myelofibrosis (a form of blood cancer) can be a long-term condition, but taking good care of yourself can help you enjoy a happier, healthier life. […] If myelofibrosis has pulled you away from work, your spirits may get a boost if you go back when you’re up to it. That can help you feel like you’re back to your normal life and get you out of the house and around other people. […] If you think fatigue or other effects of myelofibrosis could affect your work: Ask your boss if you can start part-time or work on a flexible schedule. Be patient with yourself as you build up your strength and mental focus. You might ask your doctor to write a letter explaining what myelofibrosis is and how it can affect you. […] Your medical team can help you get your weight in line.

• #6 Patient Advocacy in Myelofibrosis Care

  https://www.pharmacytimes.com/view/patient-advocacy-in-myelofibrosis-care

  Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management. […] In this segment, Mahmoudjafari directs a discussion with Nachar on the crucial role patients play in advocating for themselves and improving access to myelofibrosis treatments. Nachar emphasizes the significance of patient education on navigating the health care system and accessing medications. […] The conversation highlights the pivotal role of pharmacists in advocating for patients during multidisciplinary discussions, considering socioeconomic factors, and ensuring appropriate therapy selection. […] The discussion underscores the collaborative and proactive approach pharmacists employ to enhance patient outcomes and quality of life.

• #6 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  Although these agents are effective in reducing spleen size and improving symptoms, they do not affect disease progression. Therefore, I also evaluate all patients for allogeneic stem cell transplantation, which is the only curative modality. Appropriate patients are younger than age 75, with a low comorbidity burden and either intermediate-2 or high-risk disease. In addition, patients who do not respond to frontline JAK inhibitors should be considered for this approach. In patients who are transplant candidates, I will concurrently have them evaluated and start the process of finding a donor while initiating a JAK inhibitor. […] What are the most common adverse effects of JAK inhibitors, and how do you help patients manage these issues? There are short- and long-term effects of JAK inhibitors. Focusing on ruxolitinib, the most frequently used JAK inhibitor, patients can experience bruising, dizziness, and headaches, which generally resolves within a few weeks. Notable longer-term adverse events of ruxolitinib include increased rates of shingles infection, so I encourage my patients to get vaccinated for shingles before initiation. Weight gain has also been reported with ruxolitinib, but not with other JAK inhibitors. The other main adverse effect of ruxolitinib is worsening anemia and thrombocythemia, so I closely monitor blood counts during treatment.

• #6 What Is Myelofibrosis (MF)? | Primary Myelofibrosis

  https://www.voicesofmpn.com/myelofibrosis-information

  Don’t be afraid to talk to your doctor. You have to be proactive. You need to inform them what’s going on in your life. You need to tell them how you’re feeling. […] To try to help control the signs and symptoms of MF, Healthcare Professionals use therapies such as blood transfusions, radiation, removal of the spleen, and stem cell transplantation. People with MF may be prescribed other treatments, including but not limited to chemotherapy drugs. […] Regular monitoring and medical supervision can help identify signs of disease progression and help minimize the risk of complications. […] When you’re living with MF, you may find yourself saying that you’re fine even when you might not be. But when you don’t speak up and share how you really feel, you may miss out on the opportunity to get the care and support that you need and deserve. […] Remember, changes in your MF symptoms could be a sign that your MF is changing, too. So be sure to spell out how you really feel. Because fine is not enough.

• #6

  https://www.cancernursingtoday.com/page/myelofibrosis

  Learn more about the newest discoveries and latest clinical insights in myelofibrosis (MF). […] Cancer Nursing Today provides up-to-date perspectives and information on transplant trends in MF, novel therapeutic targets, and more. […] From promising new treatments to risk factors and prognostics, explore the latest developments in MF care. […] Anemia Support in Myelofibrosis: Dr. Bose Discusses Results of JUMP Trial Analysis. […] Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib. […] Higher Baseline Quality of Life Linked to Longer Overall Survival in Myelofibrosis. […] Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis. […] Pacritinib More Effective Than Best Available Treatment for Myelofibrosis and Severe Thrombocytopenia.

• #6 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  What are some of the key reasons why patients may develop JAK inhibitor resistance or intolerance, and how do you address these problems in clinical practice? There are a variety of reasons why patients discontinue a JAK inhibitor, but these can be lumped into 2 categories: (1) the medication has not achieved, or is no longer achieving, treatment goals, or (2) adverse effects from the JAK inhibitor require discontinuation. In a large series of patients with myelofibrosis who were treated with ruxolitinib, about 60% of discontinuations were because of JAK inhibitor refractoriness/resistance, and around 40% were from adverse events. […] Resistance can arise from several mechanisms, including activation of alternative pathways and clonal evolution that are ongoing regardless of JAK inhibition. In clinical practice, we are addressing JAK inhibitor resistance through clinical trials of novel therapies, particularly in combination with JAK inhibitors, which can potentially mitigate resistance. New JAK inhibitors are also being developed that may more effectively target the overactive JAK-signal transducer and activator of transcription (STAT) pathway and reduce resistance.

• #7 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis […] The symptoms and side effects of myelofibrosis are unique to each person, making a personalized approach to managing them essential. As a result, you will work closely with a multidisciplinary health care team that will help you manage the disease so you can maintain a good quality of life. […] Your team will draw on a broad range of services known as palliative care or supportive care. Palliative care is often confused with hospice care, but palliative care services may be used at any time during the cancer care continuum, while hospice focuses on end-of-life care. […] Supportive care addresses the physical, emotional, practical, spiritual, financial and family-related challenges of people diagnosed with cancer and their loved ones. […] Supportive care often focuses on managing physical symptoms such as fatigue, weight loss, bone and joint pain, fever, rash, night sweats, gout, headaches, Graft-versus-Host Disease (GvHD), diarrhea, mouth sores, nausea and vomiting, and abdominal pain due to an enlarged liver or spleen.

• #7 Optimizing Myelofibrosis Care in the Age of JAK Inhibitors | MDedge

  https://blogs.the-hospitalist.org/content/optimizing-myelofibrosis-care-age-jak-inhibitors

  What are some of the key reasons why patients may develop JAK inhibitor resistance or intolerance, and how do you address these problems in clinical practice? There are a variety of reasons why patients discontinue a JAK inhibitor, but these can be lumped into 2 categories: (1) the medication has not achieved, or is no longer achieving, treatment goals, or (2) adverse effects from the JAK inhibitor require discontinuation. In a large series of patients with myelofibrosis who were treated with ruxolitinib, about 60% of discontinuations were because of JAK inhibitor refractoriness/resistance, and around 40% were from adverse events. […] Resistance can arise from several mechanisms, including activation of alternative pathways and clonal evolution that are ongoing regardless of JAK inhibition. In clinical practice, we are addressing JAK inhibitor resistance through clinical trials of novel therapies, particularly in combination with JAK inhibitors, which can potentially mitigate resistance. New JAK inhibitors are also being developed that may more effectively target the overactive JAK-signal transducer and activator of transcription (STAT) pathway and reduce resistance.

• #7

  https://www.cancernursingtoday.com/page/myelofibrosis

  Learn more about the newest discoveries and latest clinical insights in myelofibrosis (MF). […] Cancer Nursing Today provides up-to-date perspectives and information on transplant trends in MF, novel therapeutic targets, and more. […] From promising new treatments to risk factors and prognostics, explore the latest developments in MF care. […] Anemia Support in Myelofibrosis: Dr. Bose Discusses Results of JUMP Trial Analysis. […] Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib. […] Higher Baseline Quality of Life Linked to Longer Overall Survival in Myelofibrosis. […] Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis. […] Pacritinib More Effective Than Best Available Treatment for Myelofibrosis and Severe Thrombocytopenia.

• #7 Myelofibrosis, Cancer, Information, Resources

  https://www.cancercare.org/diagnosis/myelofibrosis

  Cancer Care provides free, professional support services for people affected by myelofibrosis, as well as myelofibrosis treatment information and financial help with cancer-related costs and treatment co-pays. […] Oncology social workers help you cope with the emotional and practical challenges of myelofibrosis. […] People coping with serious conditions may feel many strong emotions and its common to need extra support to help get through difficult times. Patients and family members can benefit from counseling. Cancer Care services include telephone and online support groups for people with cancer and their loved ones. […] Myelofibrosis is the rarest of the MPNs and this can make finding information and support more of a challenge. Fortunately, you dont have to travel that road alone, and there are a number of groups that can assist.

• #8 Myelofibrosis Supportive Care

  https://patientresource.com/Myelofibrosis_Supportive_Care

  Myelofibrosis […] The symptoms and side effects of myelofibrosis are unique to each person, making a personalized approach to managing them essential. As a result, you will work closely with a multidisciplinary health care team that will help you manage the disease so you can maintain a good quality of life. […] Your team will draw on a broad range of services known as palliative care or supportive care. Palliative care is often confused with hospice care, but palliative care services may be used at any time during the cancer care continuum, while hospice focuses on end-of-life care. […] Supportive care addresses the physical, emotional, practical, spiritual, financial and family-related challenges of people diagnosed with cancer and their loved ones. […] Supportive care often focuses on managing physical symptoms such as fatigue, weight loss, bone and joint pain, fever, rash, night sweats, gout, headaches, Graft-versus-Host Disease (GvHD), diarrhea, mouth sores, nausea and vomiting, and abdominal pain due to an enlarged liver or spleen.

• #8 Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment | Mount Sinai – New York

  https://www.mountsinai.org/about/newsroom/2025/mount-sinai-leads-phase-3-trial-in-myelofibrosis-treatment

  Researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have demonstrated the potential for a new combination therapy to improve outcomes for patients with myelofibrosis, a rare and aggressive blood cancer. […] The trial evaluated the efficacy and safety of pelabresib plus ruxolitinib in patients newly diagnosed with myelofibrosis. […] This study suggests that combination therapy could lead to longer-lasting responses, improved disease control, and potentially extended survival. […] The data from this trial could lead to regulatory approval of combination therapy, establishing a new standard of care for early myelofibrosis management. […] The study’s robust correlative analyses further support the potential of this combination to alter disease progression, offering hope for patients who currently face a median survival of just five years.

• #8 Patient Advocacy in Myelofibrosis Care

  https://www.pharmacytimes.com/view/patient-advocacy-in-myelofibrosis-care

  Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management. […] In this segment, Mahmoudjafari directs a discussion with Nachar on the crucial role patients play in advocating for themselves and improving access to myelofibrosis treatments. Nachar emphasizes the significance of patient education on navigating the health care system and accessing medications. […] The conversation highlights the pivotal role of pharmacists in advocating for patients during multidisciplinary discussions, considering socioeconomic factors, and ensuring appropriate therapy selection. […] The discussion underscores the collaborative and proactive approach pharmacists employ to enhance patient outcomes and quality of life.

• #9 Considerations to comprehensive care for the older individual with myelofibrosis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/36333065/

  Over the last decade, we have witnessed a massive increase in available clinical agents, both in the clinical trial setting and following commercial use approval, directed to reduced life expectancy as well as the considerable symptom, splenic and anaemia burden associated with myelofibrosis. […] Given the median age of onset of the disease, coupled with an ageing population globally, we will be caring for an increasingly aged myelofibrosis cohort in future years. […] We will need to adapt our approach, emphasizing the holistic management of the older individual with myelofibrosis accordingly. […] Out with the pharmacological management of the disease, consideration needs to be given to interventions based on concurrent illness, comprehensive geriatric assessments, frailty, polypharmacy and drug-drug interactions, nutritional issues, psychological concerns (depression, anxiety or distress), cognitive decline and social/economic aspects. […] Within this review, we summarise available data addressing these issues, outline knowledge gaps and suggest a summative and holistic approach to the older individual with myelofibrosis.

• #10 ASH 2024 Symposia on MF Care – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/ash-24-peerview-mf-session-coverage

  Myelofibrosis treatment has expanded significantly in the past decade, especially with the approval of four JAK inhibitors. […] HSCT remains a cornerstone for patients with intermediate-1 or higher risk, offering long-term survival advantages. […] Anemia is a common and serious complication in myelofibrosis, often requiring transfusions. Reducing transfusion dependence is a key treatment goal. […] Patients who dont respond to JAK inhibitors may need alternative approaches. […] The session highlighted updates from the NCCN, including newer guidelines for stem cell transplants in MF. For older patients or those who dont qualify for HSCT, alternative treatments like JAK inhibitors remain essential. […] This session emphasized that myelofibrosis care is about more than just medicationsits about developing a holistic and personalized treatment plan.

• #11

  https://www.cancernursingtoday.com/page/myelofibrosis

  Learn more about the newest discoveries and latest clinical insights in myelofibrosis (MF). […] Cancer Nursing Today provides up-to-date perspectives and information on transplant trends in MF, novel therapeutic targets, and more. […] From promising new treatments to risk factors and prognostics, explore the latest developments in MF care. […] Anemia Support in Myelofibrosis: Dr. Bose Discusses Results of JUMP Trial Analysis. […] Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib. […] Higher Baseline Quality of Life Linked to Longer Overall Survival in Myelofibrosis. […] Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis. […] Pacritinib More Effective Than Best Available Treatment for Myelofibrosis and Severe Thrombocytopenia.

• #12 Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

  https://www.oncnursingnews.com/view/onco-nursing-experts-define-best-practices-treatment-considerations-for-managing-patients-with-mpns

  Patients with myelofibrosis have unique presentations and each patient has unique therapeutic needs that requires collaboration between the physician, the nurse, the nurse practitioner, that pharmacist the whole health care system to try to provide better care, Yacoub said. […] There is also a significant education need for practitioners, as well as the patients and their caregivers to teach them more about myelofibrosis, how to approach the disease, and [identify] the unmet needs so that we can work as a team to advance the field. […] The best avenue for the management of patients with myelofibrosis can evolve over time, Yacoub said, but noted that 3 goals are commonreduce splenomegaly, improve symptoms, and improve survival. […] This is a unique feature of MPNs which requires extra attention and examination by providers, Yacoub said.

Zobacz więcej